FINAL REPORT

Agreement n. S12.292277 (2000CVG3-508)
The EUROCISS Project has been implemented by a Working Group under the co-ordination of the Istituto Superiore di Sanità (ISS), Center of Epidemiology, Surveillance and Health Promotion, Rome, Italy, with the financial support of the European Commission within the Health Monitoring Programme.

The project has received financial support from the European Commission, Directorate General for Health and Consumer Protection.
Neither the European Commission nor any person acting on its behalf is responsible for any use that might be made of the following information.
The information contained in this report does not necessarily reflect the opinion or the position of the European Commission.

Partners of the EUROCISS project:

AUSTRIA
BELGIUM
FINLAND
FRANCE
GERMANY
ITALY
THE NETHERLANDS
NORWAY
PORTUGAL
SPAIN
SWEDEN
UNITED KINGDOM
EUROPEAN HEART NETWORK
This report was prepared by:

V. Benetou (GREECE)*
B. Bloemberg (THE NETHERLANDS)
P. De Smet (BELGIUM)
A. Doring (GERMANY)
M. Ferrario (ITALY)
A. Gaggioli (ITALY)
S. Giampaoli (ITALY)
S. Graff-Iversen (NORWAY)
N. Hammar (SWEDEN)
M. Kornitzer (BELGIUM)
T. Lang (FRANCE)
H. Loewel (GERMANY)
M. Madsen (DENMARK)*
L. Palmieri (ITALY)
S. Paterniti (FRANCE)
J. Pereira Miguel (PORTUGAL)
S. Petersen (EUROPEAN HEART NETWORK)
M. Rayner (EUROPEAN HEART NETWORK)
E. Rocha (PORTUGAL)
V. Salomaa (FINLAND)
S. Sans (SPAIN)
F. Seccareccia (ITALY)
K. Steinbach (AUSTRIA)
A. Trichopoulou (GREECE)*
H. Tunstall-Pedoe (UNITED KINGDOM)
D. Vanuzzo (ITALY)
M.F. Vescio (ITALY)

* See Organisation and management
## Contents

1. **Summary**  
2. **Organisation and management**  
3. **Introduction**  
4. **Aims and objectives**  
5. **Cardiovascular diseases to be considered**  
6. **Indicators: list and definition**  
   - **6.1 Health status indicators**  
     - 6.1.a Mortality  
     - 6.1.b Morbidity  
     - 6.1.c Disability  
   - **6.2 Determinants of health**  
     - 6.2.a Personal biological factors  
     - 6.2.b Health behaviours  
   - **6.3 Health system indicators**  
     - 6.3.a Medicine use  
     - 6.3.b Surgical operations  
     - 6.3.c In-patient care utilisation  
7. **Sources of information**  
   - 7.1 Hospital discharge records  
   - 7.2 Surveys  
   - 7.3 Longitudinal studies  
   - 7.4 GP networks  
   - 7.5 Registers based on administrative data  
   - 7.6 Population-based registers  
8. **Validation and quality of data**
9. Data availability

9.1 EU level

9.1.a WHO
9.1.b EUROSTAT
9.1.c OECD
9.1.d MONICA

9.2 National level

9.2.a Inventory
9.2.b Main differences between registers

10. Definition of cardiovascular

10.1 Nosologic definition

10.2 Nosographic definition

10.3 Standardised diagnostic criteria

10.3.a Acute Myocardial Infarction (WHO, MONICA, ESC–ACC)
10.3.b Unstable angina
10.3.c Ischaemic heart disease
10.3.d Heart failure (Framingham, Boston, ESC)
10.3.e Stroke (WHO, MONICA)

11. Recommended indicators

11.1 Acute myocardial infarction
11.2 Acute coronary syndrome
11.3 Ischaemic heart diseases
11.4 Heart failure
11.5 Other forms of heart diseases
11.6 Stroke
11.7 Medication use for cardiovascular diseases and their risk factors

12. Conclusions

References
Figure 1 – Data flow in population-based registers

Table 1a - WHO: HFA-DB, Hospital discharges: circulatory system disease

Table 1b - WHO: HFA-DB, Hospital discharges: ischaemic heart disease

Table 1c - WHO: HFA-DB, Hospital discharges: cerebrovascular disease

Table 2 - EU population involved in the MONICA Project for monitoring coronary events

Table 3 - EU population involved in the MONICA Project for monitoring cerebrovascular events

Table 4 - Hospital discharge records

Table 5a - Surveys at national level

Table 5b - Surveys at regional level

Table 6 - Longitudinal studies

Table 7 - General practitioner networks

Table 8 - Population-based registers for acute myocardial infarction

Table 9 - Population-based registers for cerebrovascular diseases

Table 10 - Population-based register: case definitions

Table 11 - Population-based register: case definitions

Table 12 - Conversion table between ICD–VIII, IX, and X revision

Table 13 - Indicators for acute myocardial infarction

Table 14 - Indicators for acute coronary syndrome

Table 15 - Indicators for ischaemic heart diseases

Table 16 - Indicators for heart failure

Table 17 - Indicators for other forms of heart disease

Table 18 - Indicators for cerebrovascular diseases
Acronyms

ACS = Acute Coronary Syndromes
ADL = Activities of Daily Living
AMI = Acute Myocardial Infarction
ATC = Anatomical Therapeutic Chemical
CABG = Coronary Artery By-pass Grafting
CAD = Coronary Artery Disease
CVA = CerebroVascular Accidents
CVD = CardioVascular Disease
DDD = Defined Daily Dose
DG = Directorate General
DRG = Diagnosis Related Groups
EHRM = European Health Risk Monitoring
EQ = EuroQol
EU = European Union
EUROCISS = European Cardiovascular Indicators Surveillance Set
FAO = Food and Agriculture Organisation
GP = General Practitioner
HDR = Hospital Discharge Records
HES = Health Examination Surveys
HF = Heart Failure
HFA-DB = Health For All statistical DataBase
HIS = Health Interview Surveys
HMP = Health Monitoring Programme
I = incidence
ICD = International Classification of Diseases
ID = IDentification number
IHD = Ischaemic Heart Disease
LSHTM = London School of Hygiene and Tropical Medicine
MDB = Mortality DataBase
MDC = Major Diagnostic Categories
MONICA = Monitoring trends and determinants of Cardiovascular diseases
OECD = Organisation for Economic Co-operation and Development
P = prevalence
PTCA = Percutaneous Transluminal Coronary Angioplasty
SD = Sudden Death
TIA = Transient Ischaemic Attack
WHO = World Health Organization
1. Summary

Although CVDs have been identified as one of the leading contributors to the global disease burden, the number of indicators that are considered reliable for monitoring CVD and for which data are available on a comparable bases across EU countries is currently limited. The aims of the EUROCISS project were therefore to define indicators for monitoring cardiovascular diseases (CVD) and to recommend standardised methods for future data collection in the European Union (EU). The achievement of these aims will facilitate cross-country comparisons and will assist efforts to improve the prevention and control of CVDs.

Specific project objectives included:

1. identifying which CVDs are of importance in public health;
2. identifying specific indicators for assessing morbidity;
3. developing recommendations for collection and harmonisation of data that can be easily applied within member countries to obtain reliable and significant data for the periodic monitoring of CVD.

**Objective 1 - Identifying which CVDs are of importance in public health**

In identifying the CVDs of greatest interest, two criteria have been used: high prevalence of disease, in terms of mortality, morbidity and disability; and the possibility of prevention, in terms of modifiable risk factors.

Using these criteria, the most important CVDs are acute myocardial infarction and ischemic heart diseases; heart failure; and cerebrovascular accidents.

**Objective 2 - Identifying specific indicators for assessing morbidity**

**Acute myocardial infarction**

Recommended indicators include mortality, hospital discharge rates, incidence/attack rates and case fatality. Of these indicators, mortality and hospital discharge diagnoses are available for all countries. Information about incidence/attack rate and case fatality are available in some countries through population-based registries, usually at regional level. These registries have adopted simplified procedures and methods derived from the MONICA Project, based on record linkage of mortality and hospital discharge diagnoses, and employ some validation procedures.

Prevalence of ischaemic heart diseases is assessed by surveys, but information on important clinical measures is often lacking. Recently, sensitive serologic biomarkers have become available for the identification of very small myocardial infarctions that would not have been detected earlier. The application of new, more sensitive biomarkers criteria will potentially cause a rise in the myocardial infarction incidence and a fall in the case fatality rate.
Heart failure
Heart failure is a frequent complication of myocardial infarction and hypertensive disease. Hospitalisation rates are not sufficient to evaluate the frequency of the disease, because heart failure does not necessarily require routine hospitalisation. For this reason, the EUROCISS working group suggests review of GP medical records, health examination surveys or CVD surveys and the adoption of standardised criteria. If hospital discharge records are used, validation studies are recommended because heart failure can be found under other diagnoses.
Other indicators can be used as a proxy to measure the burden of the disease if integrated with other sources of information, e.g. national consumption of drugs used to treat heart failure and its complications. Among the recommended indicators, functional disability and quality of life are suggested in patients with HF.

Cerebrovascular accidents
Recommended indicators of cerebrovascular accidents include mortality, hospital discharge rate, incidence/attack rate, case fatality, and prevalence. Of these indicators, mortality and hospital discharge diagnoses are available for all countries. Information about incidence/attack rate and case fatality of stroke is available in some countries through registries; prevalence is assessed by CVD surveys, health interview surveys and health examination survey. Special surveys at 1 year follow-up of stroke patients are recommended to evaluate the functional disability and the quality of life.

Objective 3 - Developing recommendation for data collection
The list of the new recommended indicators is based on available data and can be generated over a relatively short period of time: these we have called short-term implementation indicators. Others, called long-term implementation indicators, need a longer period of time to be implemented, and require, for each country, the training of a dedicated team of population epidemiologists to support their development.
Following the experience of many North European countries, we also recommend that all medical and death records across Europe adopt a personal identification number, which would allow an easier and more accurate record linkage among the different sources of information.
The application of the recommended indicators, validated through standard methodology in all countries will result in the availability of reliable, valid and therefore comparable data on CVD morbidity at the European level.
2. Organisation and Management

The project is a collaborative effort of different member states. Initially, twelve countries signed the agreement to participate. Two other countries (Denmark and Greece) joined the project later on. A questionnaire for the creation of an inventory of the available information sources and indicators was completed by the partner countries of the project.

A list of possible indicators and recommendations was generated during the meetings open to all formal participants. Six meetings were organised:

- Rome, 5-6 April 2001;
- Amalfi, 18-21 October 2001;
- Luxembourg, 7-8 March 2002;
- Taormina, 17-20 April 2002;
- Dresden, 28-30 November 2002;
- Varese, 8-10 April 2003.

The EUROCISS project was presented:

- at the European Society of Cardiology Working Group on Epidemiology and Prevention (Taormina, 17-20 April 2002) in the symposium Surveillance of Cardiovascular Diseases ‘The EUROCISS Project: the need for a common health currency in Europe’ (S.Giampaoli);

- at the tenth Annual Meeting of the European Public Health Association (Dresden, 28-30 November 2002): Workshop ‘Monitoring of Cardiovascular Diseases and Risk Factors: results from the EUROCISS Project’ proposed by the EUROCISS Research Group: ‘Monitoring of acute myocardial infarction and coronary heart disease’ (N. Hammar); ‘Monitoring of stroke and other cerebrovascular diseases’ (V. Salomaa); ‘Monitoring of cardiovascular risk factors’ (S. Sans); ‘Recommendations from the EUROCISS Project’ (S. Giampaoli);

- at the International Epidemiological association - European Epidemiology Federation (Toledo, 1-4 October 2003): Workshop ‘Monitoring of Cardiovascular Diseases and Risk Factors: results from the EUROCISS Project’ proposed by the EUROCISS Research Group: ‘Monitoring of acute myocardial infarction and coronary heart disease’ (N. Hammar); ‘Monitoring of stroke and other cerebrovascular diseases’ (V. Salomaa); ‘Monitoring of
cardiovascular risk factors’ (S. Sans); ‘Recommendations from the EUROCISS Project’ (S. Giampaoli);

- at the 11th Annual Meeting of the European Public Health Association (Rome, 20-22 November 2003): Workshop ‘Monitoring of Cardiovascular Diseases: results from the EUROCISS Project’ proposed by the EUROCISS Research Group: “The burden of cardiovascular diseases in Europe” (S Sans); “Recommended indicators for monitoring acute myocardial infarction and ischemic heart diseases” (N Hammar); “Recommended indicators for monitoring stroke and other cerebrovascular diseases” (S Petersen); “Recommended indicators for monitoring of heart failure and other forms of heart disease” (K Steinbach)

The following manuscripts are in press on behalf of the EUROCISS Working Group:

- Coronary and cerebrovascular population-based registers in Europe: are morbidity indicators comparable? Results of the EUROCISS Project (European J Public Health 2003;13, suppl3)

- Development of cardiovascular morbidity indicators for the European Community: the EUROCISS Project (submitted to the Italian J Public Health)
3. Introduction

The EUROCISS Project (European Cardiovascular Indicators Surveillance Set) was initiated in 2000 by a partnership of EU countries to develop health indicators and recommendations for the monitoring of cardiovascular diseases. It is part of the Health Monitoring Programme (HMP) financed by the European Commission.

Health indicators describe the health status of a community and typically include measures of mortality, morbidity and disability; they also include determinants of health (biological, behavioural and socio-demographic risk factors) and health systems (use of health services, medication use, surgical procedures). Health indicators are essential to quantify the burden of diseases.

CVDs have been identified as one of the leading contributors to the global disease burden. Fortunately, much is known about the risk factors and means of reducing CVD\textsuperscript{1-9}. Many epidemiological studies have been conducted to identify CVD risk factors and demonstrate reversibility of risk through primary and secondary prevention. Among these studies, the most important are:

- the Seven Countries Study that identified several major risk factors for CVD: smoking, a rich diet, with consequent high levels of total cholesterol, and high blood pressure. Differences in the prevalence these risk factors have been ascertained to be responsible for differences in the incidence of stroke and coronary heart disease (CHD) among participating countries\textsuperscript{1-3,6};

- the WHO European Collaborative Trial in the Multifactorial Prevention of CHD demonstrated the reversibility of risk among European populations, through healthier life styles and treatment of high risk subjects \textsuperscript{8}; in particular, the North Karelia Project represents a well-recognised approach to community-based primary prevention \textsuperscript{9};

- the WHO-MONICA Project was carried out to assess the relative contribution of CHD incidence, case fatality, trends in classical risk factors and advancements in coronary care to the decline in CVD mortality in some industrialised countries, that began in the 1970s\textsuperscript{10}. One third of the decline in CHD mortality was explained by changes in case fatality rates related to advancements in coronary care\textsuperscript{11} and two/thirds by declining incidence in coronary events, as partly explained by the reduction of classical risk factors\textsuperscript{12}.

In addition to these studies, others have contributed to the knowledge of risk factors for CVD and demonstrated that other factors such as low socio-economic status\textsuperscript{13,14}, physical inactivity \textsuperscript{15} and diabetes \textsuperscript{16} are also related to an increased risk of CVDs.
CVDs and their risk factors were also demonstrated to be associated with other adverse health outcomes including cognitive impairment, dementia and decreased physical performance in the elderly.\textsuperscript{17,18}

Overall, the major message that has emerged from all these studies is that a decrease in the level of these risk factors in the population can prevent CVDs and that a reduction of CVDs may result in considerable benefits for public health care, cost and quality of life.

4. Aims and objectives

The aims of the EUROCISS project were to identify, among existing data-sets, the essential information required to objectively define morbidity indicators for CVD and to recommend standardised methods for future data collection in the European Union. The realisations of these aims will permit cross-country comparisons and will improve prevention and control of CVD.

The objectives of EUROCISS included:
- identifying which CVDs are of importance in public health, on the basis of available knowledge, incidence, attack rate and prevalence in the population;
- identifying specific indicators for assessing morbidity in both sexes, youths, adults and older people, taking into account differences in socio-economic status across countries; this involves: taking an inventory of sources of information for selected indicators, describing methods of collection, assessing the degree of comparability and quality control necessary to enhance comparability of existing data-sets;
- developing recommendations for collection and harmonisation of data that are easy to apply within the different countries to obtain reliable and significant data for the periodic monitoring of cardiovascular morbidity in the EU.

To evaluate the health status of a population, mortality and morbidity data are necessary, together with data on prevalence of risk factors. In fact, failure to do so produces an incomplete assessment and compromises the possibilities for prevention.

For the EUROCISS it was decided to focus only on morbidity because mortality and risk factors have already been studied in other Health Monitoring Projects, in particular the European Health Risk Monitoring (EHRM). However, we are aware that to evaluate the burden of the disease in a population, data on mortality and risk factor prevalence are also necessary.
5. **Cardiovascular diseases to be considered**

Two criteria have been followed in identifying the CVDs of greatest interest: high frequency of disease, in terms of mortality, morbidity and disability; and the possibility of prevention, in terms of modifiable risk factors.

The most important CVDs are ischaemic heart diseases (IHD), which include acute myocardial infarction (AMI), acute coronary syndromes (ACS), effort angina, other forms of coronary heart disease; heart failure (HF); and cerebrovascular accidents (CVA), including ischaemic and haemorrhagic stroke. In its section on Health Status indicators, under *diseases of large impact*, the European Community Health Indicators, ECHI Project\(^\text{19}\), recommends AMI, IHD, CVA and HF within the CVDs. We would also suggest that other poorly defined CVDs of atherosclerotic origin and venous thromboembolic diseases be included as well.

In terms of importance, CVDs in Europe contribute to about 40% of overall mortality in persons 35 years and older and cause 4 million deaths each year\(^\text{20}\). IHD contributes to about 40% and CVA to an additional 25% of total CVD mortality\(^\text{21}\). Mortality data on HF are not available\(^\text{22}\). Although not currently included in most evaluations of CVD mortality, sudden death (SD) should also be considered among causes of death of interest.

Morbidity data are not available at a European level, in part because they are difficult to collect. Moreover, standardised morbidity rates are difficult to produce. One of the aims of the MONICA Project was to obtain valid and reliable information on fatal and non-fatal acute coronary and cerebrovascular events in different populations. Attack rates collected by MONICA have provided useful, accurate and reliable indicators for cross-country comparisons of acute coronary and cerebrovascular trends in men and women in the age range 35-64 years\(^\text{23}\). The MONICA study showed that for the age group 35-64 years, 1.0 to 1.5 events of hospitalised non-fatal AMI were registered for every death due to CHD\(^\text{10}\). Attack rates of acute coronary and cerebrovascular events, however, are in themselves not sufficient to describe the impact of CVDs on the population. The demographic changes in Europe with the increasing proportion of older people and the advancements in treatment have resulted in an increasing prevalence of chronic forms of IHD. Because of their frequency and cost there is a need to monitor the occurrence of both acute and chronic forms of the disease.

Interest has recently been focused on heart failure (HF) because of the poor quality of life among affected patients and the high cost of the disease. In the US it is estimated that the leading diagnosis in hospital admission of patients 65 years and over is heart failure\(^\text{22}\).
6. **Indicators: list and definitions**

Health status indicators are a set of surveillance data that has been analysed in a way that permits assessment of the health status of the population so that public health priorities and actions can be appropriately identified. The selection of indicators should be based primarily on existing and comparable data sets for which regular monitoring is feasible, but it should also take into consideration likely future data needs and diagnostic and treatment developments. Indicators should be comprehensive, valid (sensitive), standardised, meet quality criteria, and be flexible (never fixed and final) to support evolving health policies.

Based on the suggestions of the ECHI project \(^{19}\), indicators are subdivided into **health status indicators** (disease specific mortality, morbidity and disability), **determinants of health** (biological risk factors and health behaviours) and **health systems** (surgical procedures, medication use, use of health services).

### 6.1 Health status indicators

Disease-specific mortality, morbidity and disability should be available for the overall population and for age and sex subgroups. For each country or area it would be useful to have absolute numbers, crude and age-standardised rates according to a standard population (i.e. European standard population) \(^{24}\); standardisation in this case would improve comparability between countries with different age distribution in the population.

#### 6.1.a Mortality, cause specific

Mortality data may provide a crude but simple way to assess health conditions; the source of information are death certificates where the underlying cause of death is coded. The reliability of mortality data depends on the completeness and accuracy of the vital registration system of the country.

CVD causes of death are coded according to the International Classification of Diseases and Causes of Death (ICD). Problems of temporal and geographic comparisons derive from the different versions of the ICD adopted over time (8\(^{th}\), 9\(^{th}\), 10\(^{th}\) revision) and from different coding practices in each country.

**Definition of specific indicators:**

i) **crude death rate:** the number of overall and cause-specific deaths divided by estimated mid-year population per 1,000 \(^{24}\),
ii) **age-standardised death rate:** death rate estimated after age-standardisation has been performed²⁴;

iii) **age-specific death rate:** the number of deaths divided by estimated mid-year population per 1,000 for specific age groups²⁴.

### 6.1.b Morbidity, diseases specific

Morbidity can be described using the following frequency measurements: hospital discharge rate, attack/incidence rate, prevalence and case fatality. In CVDs, attack rates generally include first and recurrent events, while incidence rates represent only first event.

The importance of these measures differs according to the disease as well as the age range. In younger age groups the most important indicators are incidence, case fatality and prevalence; in older people, attack rate and prevalence are more important since patients with chronic diseases require more continuous therapy and rehabilitation, and have a greater impact on the public health system. For acute events, incidence rates are in general target measures, while for chronic conditions incidence as well as prevalence may be of interest. Incidence is used mostly for etiological research objectives; attack rate and prevalence are useful for hospital planning and for primary care.

Standardised rates are important to make cross-group comparisons and to investigate time trends, although absolute numbers are often necessary to evaluate the burden of the disease.

**Definitions of specific indicators:**

i) **hospital discharge rate or hospitalisation rate:** the number of hospital discharge records of a specified main diagnosis divided by the estimated mid-year population per 1,000²⁴;

ii) **attack rate:** the number of events (first and recurrent) divided by the estimated mid-year population per 1,000²⁴;

iii) **incidence rate:** the number of first events divided by the population at risk per 1,000 or person/years at risk. Person/years at risk consists of the sum of periods of time (years) at risk contributed by each of the person included in the study. Incidence may be estimated through the follow-up of a population enrolled in a cohort or by the identification of new events in a dynamic population. It can be obtained using longitudinal studies or disease registers, when it is possible to eliminate those who have already experienced an event²⁴;

iv) **prevalence:** the proportion of persons with the disease in a population per 100 or per 1000 at a particular time. It is assessed by surveys;
v) **case fatality:** the number of fatal cases divided by the total number of events. It is usually expressed as the percentage of persons diagnosed as having a specified CVD who die from that disease within a given period \(^2^4\).

### 6.1.c Disability

The following indicators have been used in literature to evaluate the consequences of CVD as well as the effectiveness of intervention. We propose to consider disability as a composite measure of health status according to ECHI definitions \(^1^9\).

**Definition of specific indicators:**

i) **Disability-Adjusted Life Year (DALY):** takes into account years lost due to premature mortality and years lived with disability \(^2^5\). It is equal to the sum of the number of years of life lost due to CVD in a population (YLL) and the number of years lived with disability of known severity and duration for a CVD in a population (YLD);

ii) **Potential Years of Life Lost (PYLL):** is a measure of the impact of premature mortality on the population. PYLL is the sum of the years that people dying from a CVD would have lived, had they experienced a normal life expectancy, usually determined at 65 years \(^2^4\);

iii) **Activities of Daily Living (ADL):** the ADL index measures six basic functions (moving between rooms, using the lavatory, washing and bathing, dressing and undressing, getting in and out of bed, and feeding oneself) and has a score of A (independent in every item), B (dependent in one item), C (dependent in two items), D (dependent in three items), E (dependent in four items), F (dependent in five items) and G (dependent in all functions) \(^2^6,^2^7\).

iv) **Instrumental Activities of Daily Living (IADL):** the IADL-scale measures more complex functions (using the telephone, getting to places beyond walking distance, grocery shopping, preparing meals, doing housework or handyman work, doing laundry, taking medications, managing money). The score ranges from 8 (able to perform all functions) to 0 (cannot perform any function) \(^2^8\).

v) **EuroQol (EQ):** the EQ is a standardised instrument for use as a measure of health outcome. Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status that can be used in the clinical and economic evaluation of health care as well as population health surveys \(^2^9\).
6.2 Determinants of health

Blood pressure, tobacco smoking, total cholesterol, body mass index and physical activity are important determinants of the health status of the population. In particular, it is important to have estimates on the prevalence of persons with hypertension, hypercholesterolemia, obesity, physical inactivity and smoking.

The main source of information on risk factors are CVD surveys conducted with internationally standardised procedures and methods; they are exhaustively described in the EHRM project.

Definition of specific indicators:

6.2.a Personal biological factors

i) prevalence of hypertension: number of persons with systolic blood pressure or diastolic blood pressure equal to or greater than 140/90 mmHg or under specific treatment divided by the total population. Blood pressure measurements should be obtained calculating the meaning of at least two consecutive readings 30;

ii) proportion of hypertensives under control: number of hypertensives under specific treatment with systolic blood pressure or diastolic blood pressure equal to or lower than 140/90 mmHg divided by the total number of hypertensives 30;

iii) prevalence of hypercholesterolemia: number of persons with serum total cholesterol equal to or greater than 193 mg/dl or 5.0 mmol/l or under specific treatment divided by the total population. Hypercholesterolemia should be determined from at least two consecutive tests 30;

iv) prevalence of overweight: number of persons with body mass index equal to or greater than 25 kg/m² and lower than 30 kg/m² divided by the total population 31;

v) prevalence of obesity: number of persons with body mass index equal to or greater than 30 kg/m² divided by the total population 31.

6.2.b Health behaviours

i) prevalence of physical inactivity during leisure time: available questionnaires include many integrated questions measuring time used in sport or other activities during leisure time; however it is easier to measure the prevalence of inactive persons during leisure time 32;

ii) prevalence of current, former and non smokers: number of current, former and non-smokers divided by the total population; smokers are persons who smoke one or more cigarettes a day;
iii) number of cigarettes smoked per day: number of cigarettes smoked per day divided by the total number of current smokers.

6.3 **Health system indicators**

Other indicators which measure health utilisation can be used as a proxy measures for CVD: national drug consumption, surgical operations, and use of health services. These indicators are not sufficient to evaluate morbidity, but they can be used if integrated with other sources of information.

6.3.a **Medication use**

Drug consumption figures should preferably be presented as numbers of \textit{ATC-DDDs/1000 inhabitants/day} or, when in-hospital drug use is considered, as DDDs per 100 bed days. ATC is the anatomical therapeutic chemical; DDD is the defined daily dose. Prescription data presented in DDD/1000 inhabitants/day may provide a rough estimate of the proportion of the population treated daily with certain drugs; DDD is the average maintenance dose of a medication used for its main indication in adults and assumed per day.

Drugs are classified in groups at five different levels: they are divided into fourteen main groups (1st level), with one pharmacological/therapeutic subgroup (2nd level); the 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. DDDs are assigned per ATC 5th level by the WHO Collaborating Centre for Drug Statistics Methodology in Norway \textsuperscript{33}. Drug consumption information on antihypertensives, diuretics, beta-blocking agents, calcium channel blockers, ACE-inhibitors, nitrates, anti-arrhythmics, antithrombotic agents and cholesterol and triglycerides reducers are of interest. They are used in both primary prevention and secondary prevention. However, they are not sufficient to evaluate morbidity and need to be integrated with other data, such as surveys. Thrombolytic treatment is used only in hospital in acute myocardial infarction. Drug consumption information is not very specific in the long term, because importance of medicine use changes with time.

6.3.b **Surgical operations and invasive procedures**

Surgical operations and invasive procedures, in particular \textit{coronary artery by-pass grafting} (CABG), \textit{percutaneous transluminal coronary angioplasty} (PTCA), \textit{heart transplantation}, \textit{carotid angioplasty}, \textit{pace-maker}, \textit{implantable cardioverter defibrillator}, \textit{catheter ablation} and \textit{peripheral vascular operations} are indicators of health care utilisation for CHD, stroke and other CVDs in the
population. These indicators are expressed as number of surgical operations divided by the total population.

6.3.c In-patient care utilisation and technology

Definition of specific indicators:

i) cause-specific aggregate bed-days: the number of days spent in hospital for specific disease per population;

ii) mean and median length of stay: mean and median number of days spent in hospital per patient;

iii) brain imaging: number of CT-scans or MRI per population;

iv) coronary angiography: number of coronary angiographies per population;

v) stroke unit: number of stroke units per population.

7. Sources of information

Indicators are obtained using different sources of information. The most important for CVDs are briefly described below.

7.1 Hospital discharge records

Hospital discharge records (HDR) give the number of hospitalisations by disease. Hospitalisation does not include less serious events. Problems arise when an acute event is followed by a period of rehabilitation or a transfer to other wards and the event could be counted more than once. Hospital discharge registers do not include emergency room records, seldom includes nursing homes and only in some instances private hospitals. Discharge diagnoses are rarely validated; validity may vary by case mix and total number of discharges. Hospital admission policies vary over time and place; the adoption of new diagnostic techniques, such as troponine for myocardial infarction, CT-scan and MRI for strokes, may cause major changes in event rates calculated from hospital discharge data.

In general, discharge records are more reliable than admission records. Hospital discharge data are available in most EU countries, but data may not be organised by age and sex.

Diagnosis Related Groups (DRG)

In some countries, hospital reimbursement is based on the DRG tariff system. The DRG system is based on equal-resources criteria and aggregates events in major diagnostic categories (MDC). Homogeneous groups of patients are defined as those requiring similar facilities, similar levels of
organisation and diagnostic procedures. This system has been used in the United States for over 10 years, and is the basis for the prospective payment system of hospital stay for Medicare patients (elderly over 65 years). DRG may be useful in hospitals for acute events, but are not reliable for chronic diseases requiring a long hospital stay and rehabilitation. The DRG system takes into account the main hospital discharge diagnosis according to the MDC, complications, age and sex.

The main hospital discharge diagnosis is the condition identified for reimbursement of treatments and/or diagnostic procedures. Hence, information is synthesised and organised by economic objectives that could overestimate or underestimate seriousness, complications and co-morbidity; i.e. stroke units or specialist wards may selectively admit the most severe cases. For this reason, the use of the hospital discharge diagnosis may be misleading in countries applying the DRG tariff system. One of the advantages of the DRG tariff system, however, is its availability for the entire population of a country. This overcomes one of the drawbacks of hospital records, which is the difficulty of determining the population denominator by identifying the total country population as a reference.

Countries using the DRG system are Denmark, Finland, France, Italy, Norway, Portugal, Spain and Sweden. Countries where the DRG system will be implemented in the near future are Germany and the Netherlands.

7.2 Surveys

Health Interview Surveys (HIS) may be part of a permanent system of data collection at a national level. They are usually repeated periodically; information is self-reported and may not be sufficient to assess CVD morbidity. High costs of clinical examination make the Health Examination Surveys (HES) difficult to carry out; they are usually based on a general broad health focus and conducted at regional level. Only few HIS and HES use properly standardised and sensitive methods to assess CVD morbidity.

Ad hoc CVD surveys provide important information on risk factors and disease prevalence but are seldom representative of the whole country. They are usually conducted on adults and often exclude subjects older than 70 years. Their reliability depends greatly on the participation rate and methodologies adopted. If conducted in representative population samples, they may provide a reliable estimation of CVD prevalence. Standardised procedures and methods are available[^34], such as the questionnaires from the London School of Hygiene and Tropical Medicine (LSHTM), used to identify angina pectoris, myocardial infarction and intermittent claudication. These have been used for many years in population studies and are available in different languages. They may evaluate
the presence of symptoms, of great importance for the health system when evaluating the burden of disease because not only the acute manifestations of the diseases, for example, myocardial infarction, but also the symptoms, for example, chest pain, contribute to the use of health services and to health costs. ECG, read according to the Minnesota Code (the Minnesota Code changes qualitative diagnoses into quantitative results), blood pressure, weight, height, total and HDL-cholesterol are usually collected to assess cardiovascular disease and risk factors. Echocardiography is recommended to make a reliable diagnosis of heart failure.

7.3 Cohort longitudinal studies

Cohort longitudinal studies are usually very comprehensive: they enrol a large healthy population, measure risk factors and observe over a long period, commonly years, the development and evolution of the disease. Incidence of disease can be determined in groups that differ in exposure level. These studies are very expensive, therefore seldom used for studying rare diseases, for example, CHD in women. They are useful for both etiologic and public health administrative purposes. Their validity depends greatly on the representativeness of the enrolled population and on the number of persons lost during the follow-up. Almost all countries of the European Union have ongoing longitudinal studies of CVDs. They include relatively small samples of the population and in general involve collecting and validating hospital discharge diagnoses and deaths of the enrolled cohort. Diagnostic criteria for the definition of CVD events are specific to each study. Diagnostic criteria are based on history, clinical examination, hospital records, blood tests, and autopsies in cases of death.

Cohort longitudinal studies have contributed to the understanding of the differences in incidence across countries, to the measurement of the importance of risk factors in the prediction of disease and to the establishment of causality. Other longitudinal studies are those following cohorts of patients enrolled through registers. These studies lack the information on risk factors at baseline; they are defined as \textit{long-term survival of population-based registers}.

7.4 GP networks

In some countries networks of general practitioners (GP) can be useful when dealing with conditions not necessarily requiring hospitalisation. They may provide an adequate coverage for prevalence of chronic conditions such as IHD or HF. In a few countries these networks are operative (e.g. The Netherlands and UK). Information on this source has been exhaustively covered by the Project Health Monitoring in Sentinel Practice Network. GP networks may be affected by
selection bias; usually not all GPs participate in studies but only volunteers. Data from GP networks require validation.

7.5 **Registers based on administrative data**

In some countries registers are available, based on record linkage of mortality and hospital discharge records. These registers have existed for many years in a number of Nordic countries, where individuals are identified by a personal identification number (ID) thus allowing record linkage of all information sources. These registers are economical, cover the whole country, all age groups and collect large numbers of events; they are limited because they are not planned for scientific research and data are not standardised. Changes in the ICD version or the introduction of new diagnostic criteria may have unpredictable effects. These registers can be used when carefully validated 36-41.

7.6 **Population-based registers**

Population-based registers are usually formed through the linkage of various sources of information (mortality data, hospital discharge and GP records) and the validation of suspected events. Registers cover large samples of the population, usually entire municipalities. Case finding (in- and out-of-hospital events, in-hospital events which occurred out of the region, home treatment events) and validity depend on the health system, medical care and diagnostic criteria applied in the definition of events. Potential sources of bias are the following: incompleteness of hospital records, death certificates and autopsy records; coding errors; inaccuracy and non-comparability of the diagnostic criteria and autopsy rate.

The accuracy of rates produced using registers is related to the completeness and quality control of the data collected for the numerator (death and hospital discharge registers) and the denominator (population). Completeness also involves tracing subjects treated outside hospitals (nursing homes, clinics). In order to have a valid population-based register, the register should also collect events that happen to the residents but occur outside the area of surveillance. Data inaccuracy may be a problem for stroke: 50% of “new stroke diagnoses” are merely sequelae of an old stroke 41. This problem increases with ageing 42. Deaths occurring within 28 days are considered to reflect the same event. A unique ID for each subject would be very useful in linkage procedures between hospital discharge diagnoses and death certificate data sets; alternatively, multiple variables (e.g. name, date of birth, sex, residence) deterministic or probabilistic methods can be used for record linkage. Figure 1 shows the data flow in a population-based register.
The identification of events can be obtained by *hot pursuit* or *cold pursuit*. Hot pursuit means identifying case admissions to hospital usually within one or two days from the event onset and acquiring relevant information by visiting the ward or interviewing the patient. Information bias is minimised by the *hot pursuit* approach as information is collected immediately after the event. The process is expensive. The method was used in the WHO European Office Myocardial Infarction Registers in 1970 and in the WHO MONICA project. *Cold pursuit* implies the use of routine and delayed procedures, hospital discharge and death records. The process is easier and less expensive than hot pursuit; the number of cases studied is smaller because discharge diagnoses are more precise and specific than those on admission, but there is a possibility of missing important information. Both methods are used to identify suspected events, which must be validated applying the criteria of the WHO community register, or the MONICA methodology, or the new criteria of the European Society of Cardiology.

Registers are the best and most feasible source of morbidity data at a population level; they provide key indicators such as attack rate and case fatality. Incidence can be assessed if information on first event is available. If survival rates are available, also prevalence can be assessed.

The high cost of registers limits their implementation at a national level; therefore, they should be established in representative areas of a country (regions, macro-areas, etc). Several countries have registers for acute myocardial infarction (Belgium, Denmark, Finland, France, Germany, Italy, Norway, Spain and Sweden), fewer have them for stroke (Finland, France, Germany, Italy, Norway and Sweden). Most adopt simplified methods derived from the MONICA project, which involves record linkage of death, hospital discharge and autopsy; almost all apply the MONICA diagnostic criteria for the validation of all suspected events, or on a random sample or periodically.

### 8. Validation and quality of data

A measure of health status must not only be reliable but also valid. An indicator is valid if it measures the disease or condition it claims to measure. Validation evaluates the sensitivity and specificity. To validate coronary events collected within registers, the WHO diagnostic criteria, or the MONICA diagnostic criteria or the New Criteria of the Joint ESC/ACC, described later in this report, are applied as *gold standard*.

Validation can be carried out in all or in a sample of suspected cases; the choice will depend on factors such as the type and the frequency of the disease and the precision desired. Examples of
validation procedures are: first 500 cases identified in one year; all cases during one month; or a randomly selected sample. In order to produce validated indicators, a *conditio sine qua non* is to allow the epidemiological teams involved in the validation access to relevant medical records and routine raw data of health statistics.

Quality of data depends on:

- completeness of coverage in terms of cases and place of treatment (hospitals, nursing homes, clinics, etc.);
- completeness of records and information (date of admission, date of discharge, ID, gender, hospital discharge diagnostic codes, intervention/procedure codes, department/ward, date of birth);
- methods for checking duplicate records;
- methods for record linkage between different sources of data;
- consistency of coding with the diagnosis;
- autopsy rate, especially for out-of-hospital events;
- consistency of coding/comparability of the information for different areas of the country;
- consistency of coding over time;
- representativeness of the different areas in the country.

9. **Data availability**

9.1 **Databases available at a European level**

9.1.a **WHO statistical databases**

WHO produces two main health databases: the WHO Mortality DataBase (MDB) and the Health for All Statistical DataBase (HFA-DB)\(^{48,49}\).

Both WHO databases contain data on about 600 health indicators, including basic demographic and socio-economic indicators; some lifestyle and environment-related indicators; mortality, morbidity and disability; hospitalisations; and health care resources, utilisation and expenditure. They allow a simple and user-friendly analysis of trends and international comparisons for a wide range of health statistics to support the formulation and monitoring of health policies at a national and international level.

The HFA-DB is used by the WHO for the routine analysis and assessment of the health situation in Europe; it provides easy and rapid access to a wide range of basic health statistics for the 51
Member States of the WHO European Region (including countries of the former Soviet Union). It was developed by the WHO Regional Office for Europe in the mid-1980s to support the monitoring of health trends in the Region.

The data are either submitted by the European Member States to the Regional Office or collected from other international organisations or sources. The Regional Office continuously collects new data and issues updated versions of the database twice a year, generally in January and June. The most recent version was issued in June 2003. The data is presented in a user-friendly, graphical or tabular form.

There are two versions of the database:

- An **on-line** version, which allows rapid access to the data via the Internet; and
- An **off-line** version, which can be downloaded from the Regional Office Website.

Mortality data by leading causes and more detailed age-groupings are available in the off-line HFA-DB supplementary database (HFA-MDB).

Along with standardised overall mortality rates, estimates are also available separately for men and women, for all combined ages or grouped into 0-65 or over 65 years, and for various calendar years.

For CVD morbidity, the HFA-DB website provides the indicators listed below for each country:
- number of hospitalisations for circulatory system diseases;
- hospitalisation rates/100,000 for circulatory system diseases, ischaemic heart diseases and cerebrovascular diseases (tables 1a,1b,1c);
- new cases of ischaemic heart diseases and new cases of cerebrovascular diseases;
- incidence of ischaemic heart diseases/100,000 and incidence of cerebrovascular diseases/100,000; a message warns that “There is no regular data collection for incidence and ad hoc sources are used when available; therefore, availability of data for this indicator is very limited. Furthermore, this indicator cannot be used for comparisons between countries and/or time periods on account of the great differences in national definitions and registration practices”.

Not all morbidity indicators are available by sex or age groups. In particular, in the HFA-DB only a relatively small number of indicators are directly collected from each country.

*Tables 1a, b and c* report, as an example, years of the first and last available data, and the sources of the indicators mentioned.

Limitations involving the use of the morbidity WHO-HFA database can be summarised as follows:
- definitions of morbidity indicators are lacking;
- morbidity data are not available by ICD code; they are grouped within the nosologic definition as circulatory system diseases, ischaemic diseases, and cerebrovascular diseases;
- morbidity data are not available by sex and age;
- morbidity data are not always available for the same calendar years.

9.1.b **EUROSTAT (The statistical office of the European communities)**

EUROSTAT was established in 1953 to meet the requirements of the Coal and Steel Community. Over the years, its task has broadened and, when the European Community was founded in 1958, it became a Directorate General (DG) of the European Commission. EUROSTAT is the only provider of statistics at the European level; its key role is to provide statistics to other DGs and to the Commission, and to other European Institutions in support of their role in defining, implementing and analysing Community policies.

EUROSTAT’s main role is to process and publish comparable statistical information at the European level. Its efforts are directed towards a common statistical ‘language’ that embraces concepts, methods, structures and technical standards. EUROSTAT does not collect data: these are provided by the Member States. EUROSTAT’s role is to consolidate the data, ensuring comparability through the use of harmonised methodology.

Health statistics cover all 15 Member States as well as Iceland, Norway and Switzerland. EUROSTAT integrates information from the most relevant data sources existing at an international level: the OECD (Organisation for Economic Co-operation and Development), WHO, the FAO (Food and Agriculture Organisation), etc. Data are available from as far back as 1960 in some cases. Most EUROSTAT publications and data are available for a fee on the Internet.

Information and tables about cardiovascular disease morbidity are included in the first edition of the publication *Key data on health 2000 – Data 1985-1995*. This publication, which appears at regular intervals, offers a set of systematic and official statistics that are directly relevant to Community health policies. The publication is divided into six chapters: the first presents data on populations; the second focuses on lifestyle issues; the third describes health risks associated with the environment, working conditions and leisure time; the fourth describes the health status of EU populations. Chapter four contains the graphs *Age-standardised myocardial infarction incidence rates per 100,000 (35-64 age)* and *Case fatality rates at 28 days* (graph. 4.4.32), using data from the MONICA project. Chapter five presents a detailed picture of mortality, while the last chapter gives an overview of the health care system.
9.1.c OECD

The Organisation for Economic Co-operation and Development (OECD) provides the OECD-Health Data 2002, a unique software package consisting of an interactive database and query modules to provide a user-friendly tool for the comparative analysis of health systems within and among the 30 OECD Member countries. It is available for a fee on the Internet. Available in CD-ROM, this 11th edition contains more than 1,200 indicators across 30 countries for 1999/2000, with some time series as far back as 1960.

The OECD also provides OECD Health Data 2001, an essential tool for all those concerned with the analysis and strategic planning of resource allocation within and between national health care services of the OECD countries. It is available for a fee on the Internet.

Data is gathered from different sources, mainly from public institutions such as Ministries of Health and Welfare, National Statistical Institutes, Research Institutes and hospital morbidity databases. All users of data on cross-national comparisons of health care should be reminded that there are still important gaps with respect to international agreements on statistical methods. The same term may refer to different indicators within the 30 OECD countries.

Under the Ageing-Related Disease Project, for the Study of Cross National Differences in the Treatment, Cost and Outcome of Ageing-Related Diseases, a final report with data on mortality, morbidity health system indicators and determinants of health is available on AMI, IHD and stroke.

9.1.d MONICA – Monitoring cardiovascular disease

The WHO MONICA (MONItoring trends and determinants of CArdiovascular diseases) Project was developed to answer questions arising from the 1978 Bethesda Conference on the decline in CHD mortality.

MONICA aimed at measuring, within defined populations, 10-year trends of CHD and stroke, and their case fatality rates; trends in CVD risk factors; and trends in acute coronary and stroke health care for men and women, 35 to 64 years of age. Indeed, MONICA has provided a unique opportunity for exploring the relationship between CVD morbidity and mortality.

Tables 2 and 3 list the EU countries involved in MONICA surveillance during the first 3 years of the study (1985-87).

Public access to MONICA data is available at the MONICA website. The website provides quality assessment reports on coronary and stroke event registration and demographic data.
Fatal and non-fatal coronary events are reported as the total number of definite coronary events for each year, with separate totals for men and women, for the age range 35-64 years. The data are also presented as crude percentage of first, recurrent and indeterminate events from previous history.55

Fatal and non-fatal stroke events are reported for each year, and separately for men and women, as the total number of definite strokes, stroke following a coronary event and non classifiable because of insufficient data; for the age ranges 35-64 and 65-74 years, data are also presented as crude percentages of first and recurrent events.56

9.2 Databases available at a national level and methodologies adopted

9.2.a Inventory

For the previously mentioned sources of information (HDR, surveys, registers, cohort longitudinal studies and GP networks), tables were developed to summarise the available data, providing a comprehensive overview and facilitating a comparison between countries.

Table 4 reports information about HDR. In all countries HDR cover almost the entire population, both sexes and all ages. National reimbursement systems based on DRG are applied in all countries except Austria, Belgium, Germany, The Netherlands and the UK. ICD-9 is used in Belgium, Italy, The Netherlands, Portugal and Spain. Linkage with mortality is possible for Denmark, Finland, The Netherlands, Sweden and the UK by different methods: ID in Denmark, Finland and Sweden; date of birth, sex and zip code in The Netherlands and UK. The in-hospital case fatality is computed in all partner countries except Belgium and Spain. In Finland the validation of HDR is implemented; in other countries validation is not performed (Austria, Belgium, Germany, Italy, The Netherlands, Norway) or has been performed by retrospective review on an ad hoc basis (Sweden and Denmark) or only in a sample of the population (France and Spain).

Data are generally accessible with previous written request of authorisation, through national health or statistical institutions.

Tables 5a and 5b provide the main surveys on CVDs. HIS performed by national statistical institutes are included in Table 5a; they usually report generic questions on health conditions and use a self-reported questionnaire. Therefore, some conditions such as the prevalence of hypertension and diabetes could be underestimated.

Finland, Germany, Italy, The Netherlands, Portugal and Spain carry out CVD surveys periodically (Table 5b). All these include the LSHTM questionnaire for the evaluation of symptoms, medical examination and ECGs.
Information is available for 20-80 year-old men and women. The response rate is over 60% in all countries except in the MORGEN survey in The Netherlands (55%). The majority of CVD surveys adopt MONICA standard methodologies \(^{58}\), WHO standard methods are used in CARDIO 2000 (Greece) and ERGO (The Netherlands) \(^{34}\). Data are accessible through national health or statistical institutions, universities and MONICA reference centres.

The available information on cohort longitudinal studies is summarised in **Table 6**. These studies are performed in Belgium, Denmark, Finland, France, Germany, Italy, The Netherlands, Sweden and the UK. Age ranges between 20 and 84 years. Cohort longitudinal studies are predominantly performed at a regional level. Most do not include HF. Denmark and the UK include HF as well as The Netherlands. Some started in the 80’s (Belgium, Germany-KORA, Italy-Osservatorio Epidemiologico Cardiovascolare, The Netherlands-Zutphen and Doetinchem), some in the 90’s (France-PRIME, The Netherlands-ERGO, Sweden-Stockholm), and others more recently, in the year 2000 (Finland-HEALTH 2000 and Germany); the Finland FINMARK started in 1972 and the British Regional Heart Study in 1978. The data are accessible through national health institutes or universities.

GP networks provide data only in The Netherlands, Portugal and UK (**Table 7**).

**Table 8** reports information on AMI from population-based registers. AMI registers are ongoing in Belgium, Denmark, Finland, France, Germany, Italy, Norway (Finnmark) and Sweden. Most of them started between the second half of the 80's and the first half of the 90's (Belgium, Finland, France, Germany, Italy, Spain and Sweden); others are more recent (Norway), while the Danish register goes back to 1978. Age of persons included ranges between 25 and 74 years or more. Many of the population-based registers adopt simplified methodologies derived from the MONICA Project and validate the events applying the MONICA diagnostic criteria. Administrative registers, based on a record linkage methodology covering the entire population and all ages, have been established in Denmark, Finland and Sweden. They have been validated by retrospective examination of medical records and by linkage to MONICA registers. The existence of national registers of hospital discharges and deaths that may be linked using unique personal ID make the proposal of national registers possible. Currently, discussions on making joint comparative studies based on these national registers are taking place in the Nordic Countries.

Data available from stroke population-based registers are summarised in **Table 9**. They are less frequent than AMI registers. The surveillance system is carried out on a regional or local basis in all countries (Finland, France-Dijon, Germany, Italy, Norway and Sweden-MONICA). Denmark,
Finland and Sweden also have an administrative register, which covers the entire population. The Swedish national register, however, is a hospital-based register set up primarily to evaluate treatment for stroke.

9.2.b Main differences between registers
In different countries AMI and stroke population-based registers use different procedures for the selection of events. Record linkage of mortality and HDR and validation methods are reported in Table 10.

Different causes of death are considered in the selection of AMI events: the Swedish national AMI register includes only AMI (ICD-9 410). All other registers include IHD (ICD-9 410-414); Belgium and Spain add HF (ICD-9 428) to these codes; Finland, Germany and Norway add SD (ICD-9 798). Italy considers other causes of death (e.g. diabetes and hypertension) where one of the contributory causes of death is IHD; France limits the selection to IHD.

From HDR, selected causes for events are as follows: AMI (ICD-9 410) in Sweden; and AMI and other acute and subacute forms of ischaemic heart disease (ICD-9 411) and angina pectoris (ICD-9 413) in Finland. Denmark, Italy and Spain collect data on IHD (ICD-9 410-414); Norway adds HF (ICD-9 428) and PTCA; and Belgium and Germany add the CABG.

Linkage procedures between mortality and HDRs are automatically performed through the ID in Denmark, Finland, Norway and Sweden, and through name, date of birth, and place of residence in Germany and Italy. Linkage procedures are manual in Belgium, France and Spain.

Selection procedures of events, age range and attack rates, which are not stratified by, make data difficult to compare. There are ongoing discussions in the Nordic countries on how comparability may be achieved when comparing data based on routinely collected information from hospital discharges and deaths.

Table 11 summarises the codes used for the selection of stroke. Denmark, Finland, France-Dijon, Germany and Norway select all CVDs for mortality and HDRs; Italy does not include transient ischaemic attack (TIA ICD-9 435) either for mortality or HDR, Sweden does not include TIA, other and ill-defined cerebrovascular disease (ICD-9 437), and the late effects of cerebrovascular disease (ICD-9 438).

All stroke registers adopt the personal ID number except for Italy, which links mortality and HDRs by name, birth date and place of residence. Validation is based on MONICA diagnostic criteria in Finland, Italy, Norway and Sweden. Validation makes use of health insurance data in Germany and
CT-scans in France-Dijon. The national Sweden stroke register (Riks-stroke) does not include subarachnoid haemorrhage, ICD-9 430.

10. Definition of cardiovascular diseases

10.1 Nosologic definitions

Acute myocardial infarction: myocardial cell death due to prolonged ischaemia \(^49\).

Acute coronary syndrome: it is a big category which includes myocardial infarction, both Q-wave and non-Q-wave, and unstable angina. Unstable angina is an acute ischaemia without myocardial necrosis (410-411-413).

Angina pectoris: a pain in the chest and/or adjacent area associated with myocardial ischaemia but without myocardial necrosis \(^49\). It is an old term used to describe myocardial ischaemia without necrosis. It is generally divided into unstable, which is part of acute coronary syndrome, and stable angina.

Ischaemic heart diseases and coronary heart diseases: are commonly due to the obstruction of coronary arteries by atheromatous plaques. These include acute myocardial infarction, other symptomatic and asymptomatic (silent) myocardial ischaemia, old myocardial infarction, angina pectoris, and other forms of chronic ischemic heart disease. Generally speaking, congestive heart failure, cardiac arrhythmias and sudden death recognise the same etiology. There are also non-atherosclerotic causes of obstructive coronary artery diseases (CAD). Myocardial ischaemia may also occur in the absence of obstructive CAD, as in the case of aortic valve disease, hypertrophic cardiomyopathy, idiopathic dilated cardiomyopathy, and luetic aortitis \(^60\); they are rare.

Heart failure: it is a pathophysiological state in which an abnormality in cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirements of metabolising tissues \(^49\). Hypertension, myocardial infarct, and coronary heart disease are the major causes of heart failure.

Cerebrovascular accidents: stroke is characterised by rapidly developing clinical symptoms and signs of focal, at times global, loss of cerebral function lasting more than 24 hours or leading to death, with no apparent cause other than that of vascular origin \(^49\).

There are four main types of stroke: two caused by blood clots or other particles and two by haemorrhage. Ischaemic stroke (thrombosis and embolism) is the most common, accounting for about 70-80% of all strokes \(^49\).
Cerebral thrombosis: it occurs when a blood clot (thrombus) forms and blocks blood flowing in an artery that supplies blood to part of the brain. Blood clots usually form in arteries damaged by atherosclerosis.

Cerebral embolism: it occurs when a clot (an embolus) or some other particle formed in a blood vessel, usually in the heart, is carried in an artery leading to or in the brain, blocking the flow of blood. The most common cause of embolism is atrial fibrillation.

Subarachnoid haemorrhage: it occurs when a blood vessel on the surface of the brain ruptures and bleeds into the space between the brain and the skull.

Intracerebral haemorrhage: it occurs when a defective artery in the brain bursts, flooding the surrounding tissue with blood.

Other cardiovascular diseases: include rheumatic heart disease, hypertensive heart diseases, other forms of heart diseases, atherosclerosis, aortic aneurysm, acute cor pulmonale, dysrhythmias, acute pulmonary oedema and venous thromboembolic diseases.

10.2 Nosographic definitions

Table 12 shows the diseases and their codes following the ICD, 8th, 9th, and 10th Revisions. Most countries have recently adopted ICD-10 Revision, however ICD-9 is still used by almost all countries for coding HDRs, because of the classification of procedures (ICD9-CM). In 1996 the Nordic Medico-Statistical Committee (NOMESCO) published the Classification of Surgical Procedures adopted in the five Nordic Countries (Denmark, Sweden, Finland, Norway, and Iceland).

10.3 Standardised diagnostic criteria

Diagnostic criteria are used to validate clinical diagnoses. Those used in standardised studies are here reported in detail.

10.3.a MYOCARDIAL INFARCTION

WHO criteria

Myocardial infarction is defined as definite on the basis of history, ECG, enzyme and necropsy, as follows:

1) ECG with unequivocal serial changes, or 2) typical history or atypical history together with equivocal ECG and elevated enzymes, or 3) typical history and elevated enzymes with negative or non available ECG, or 4) fatal cases whether sudden or not, with naked-eye appearance of fresh
myocardial infarction and/or recent coronary occlusion at necropsy (ante-mortem thrombus, haemorrhage into an atheromatous plaque or embolism).

**MONICA criteria**

*Non-fatal coronary events* are classified as *definite* and *possible*. The major difference with the WHO criteria is the use of the Minnesota code, a quantitative system for coding ECGs. Non-fatal events are classified as *definite* and *possible*. The major difference with the WHO criteria is the use of the Minnesota code, a quantitative system for coding ECGs. A *definite* non-fatal event is defined as:

1. Progression of Minnesota codes on serial ECGs,
   - Progression from no Q-wave to a definite Q-wave; or
   - A lesser Q-wave progression combined with progressive ST-segment depression, developing ST-segment elevation, or progressive T-wave inversion; or
   - Persistent ST-segment elevation with progressive T-wave inversion in sequential daily ECGs, or
2. Cardiac enzyme levels two times the normal cut-off point, either with typical symptoms and an abnormal ECG, or with lesser symptoms and an ECG progression labelled *probable*.

Non-fatal events are placed in the category *possible* if a typical prolonged chest pain (20 minutes) occurs together with lesser or no ECG and enzyme findings.

*Fatal coronary events* are classified as *definite*, *possible*, and *unclassifiable*.

Events are *definite* if they satisfy the following criteria:

- definite criteria reported for non-fatal events; or
- when autopsy shows recent myocardial infarction or coronary thrombosis.

*Possible* coronary death involves suggestive terminal symptoms, or a CHD history in the absence of chronic occlusive CHD, or old myocardial infarction without pathological findings suggestive of a fatal disease.

**Limitations of the coronary MONICA criteria**

The MONICA Project provides thorough information on mortality and morbidity, diagnostic criteria, standardisation, validation, quality control and data comparability for the years 1985-1994. Consistent methodology and diagnostic criteria were used to identify coronary events over time. The methodology was expensive, however. Available indicators were attack rate and fatality rate. There are some aspects that limit the study’s generalisability:

- the age group under surveillance was limited to 35-64 year old individuals;
- areas selected for the study were those registering 100 to 300 coronary deaths in men below age 65 years;
- the selected areas were not necessarily representative of the whole country;
- it could not identify silent forms of myocardial infarction and misdiagnosed events.

**New Criteria of the Joint ESC/ACC Committee for the Redefinition of Myocardial Infarction**

Recently, sensitive and specific serologic biomarkers have become available for the identification of very small myocardial infarctions that would not have been detected earlier. The biomarker of myocardial damage is cardiac troponine, which has nearly absolute myocardial tissue specificity, as well as a high sensitivity.

The application of these new, more sensitive criteria for MI will potentially cause the rise of MI incidence and the fall of case fatality rate. Thus, the new definition of MI may confuse efforts to follow trends of disease rates in populations. Continued tracking of these trends will require methods for adjusting to the new criteria.

**Criteria for acute, evolving or recent AMI**

Either one of the following criteria satisfies the diagnosis for an acute, evolving or recent AMI:

1. Typical rise and gradual fall (troponine) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least one of the following:
   - (a) Ischaemic symptoms;
   - (b) Development of pathologic Q-waves on the ECG;
   - (c) ECG changes indicative of ischaemia (ST-segment elevation or depression); or
   - (d) Coronary artery intervention (e.g., coronary angioplasty).

2. Pathologic findings of an acute MI.

**Criteria for established MI (past)**

Anyone of the following criteria satisfies the diagnosis for established MI:

1. Development of new pathologic Q-waves on serial ECGs. The patient may or may not remember previous symptoms. Biochemical markers of myocardial necrosis may have normalised, depending on the time elapsed since the infarct developed.

2. Pathologic findings of a healed or healing MI.

**Limitations of the Joint ESC/ACC criteria**

These new criteria, based on the rise and fall of the cardiac troponine marker, can be observed if myocardial infarction comes under care immediately after the onset of symptoms and the patient survives for several days, in order to guarantee the fall of the biochemical marker. Therefore the definition is not comprehensive of fatal cases.
10.3.b UNSTABLE ANGINA

According to the New Criteria of the Joint ESC/ACC Committee unstable angina is defined as an ACS with no ST-segment elevation at the ECG and no elevation of biochemical markers such as troponine or CK-MB measured by mass assay 67.

10.3.c ISCHAEMIC HEART DISEASE

The LSHTM questionnaires for angina pectoris on effort and myocardial infarction identify the characteristics of ischaemic pain - i.e., occurrence usually on walking, in certain chest site, usually causing the individual to slow his pace or stop, and promptly relieved by rest. ECG Minnesota Code provides a framework for uniform reporting in reasonably homogeneous, precisely defined classes, and includes instructions to reduce coding variability. Definition of the Minneota ECG Codes are given in the Publication of Rose and Blackburn34; diagnostic criteria for IHD are reported in the publication of Keys 35:
- major Q-waves corresponding to Minnesota Codes 1.1
- lesser Q-waves plus major T-wave findings, corresponding to Minnestoda Codes 1.2 plus 5.1 or 1.2 plus 5.2
- major specific resting ECG abnormalities corresponding to one of the following Minnesota codes: 1.2, 1.3; 5.1, 5.2; 6.1, 6.2; 7.1, 7.2, 7.4 or 8.3.

10.3.d HEART FAILURE

Framingham Criteria 22

Criteria for HF as specified in the Framingham Study may be distinguished into major and minor criteria.

Major criteria include:

- paroxysmal nocturnal dyspnoea
- neck vein distension
- rales
- radiographic cardiomegaly (increasing heart size on chest X-ray film)
- acute pulmonary oedema
- third sound gallop
- increased central venous pressure (>16 cm water in the right atrium)
- circulation time ≥ 25 seconds
- hepatojugular reflux
- pulmonary oedema, visceral congestion or cardiomegaly at autopsy
- weight loss ≥ 4.5 kg in 5 days in response to treatment of HF.

Minor criteria include:
- bilateral ankle oedema
- nocturnal cough
- dyspnoea on ordinary exertion
- hepatomegaly
- pleural effusion
- decrease in vital capacity by 33% from maximal value recorded
- tachycardia (rate ≥ 120 beats/min)

Diagnosis of HF is given for two major or one major and two minor criteria.

**Boston Criteria**

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Point value [*]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Category I: history</strong></td>
<td></td>
</tr>
<tr>
<td>Rest dyspnoea</td>
<td>4</td>
</tr>
<tr>
<td>Orthopnea</td>
<td>4</td>
</tr>
<tr>
<td>Paroxysmal nocturnal dyspnoea</td>
<td>3</td>
</tr>
<tr>
<td>Dyspnoea while walking on level area</td>
<td>2</td>
</tr>
<tr>
<td>Dyspnoea while climbing</td>
<td>1</td>
</tr>
<tr>
<td><strong>Category II: physical examination</strong></td>
<td></td>
</tr>
<tr>
<td>Heart rate abnormality</td>
<td>1 if 91 to 110 beats per minute</td>
</tr>
<tr>
<td></td>
<td>2 if more than 110 beats per minute</td>
</tr>
<tr>
<td>Jugular venous elevation</td>
<td>2 if greater than 6 cm H2O</td>
</tr>
<tr>
<td></td>
<td>3 if greater than 6 cm H2O plus hepatomegaly or oedema</td>
</tr>
<tr>
<td>Lung crackles</td>
<td>1 if basilar</td>
</tr>
<tr>
<td></td>
<td>2 if more than basilar</td>
</tr>
<tr>
<td>Wheezing</td>
<td>3</td>
</tr>
<tr>
<td>Category III: chest radiography</td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--</td>
</tr>
<tr>
<td>Alveolar pulmonary oedema</td>
<td>4</td>
</tr>
<tr>
<td>Interstitial pulmonary oedema</td>
<td>3</td>
</tr>
<tr>
<td>Bilateral pleural effusion</td>
<td>3</td>
</tr>
<tr>
<td>Cardio thoracic ratio greater than 0.50</td>
<td>3</td>
</tr>
<tr>
<td>Upper zone flow redistribution</td>
<td>2</td>
</tr>
</tbody>
</table>

[*] The composite score (the sum of the subtotal from each category) has a possible maximum of 12 points. The diagnosis of heart failure is classified as definite at a score of 8 to 12 points, possible at a score of 5 to 7 points, and unlikely at a score of 4 points or less.

**ESC definition of HEART FAILURE**

1. Symptoms of heart failure (at rest and during exercise)
   and

2. Objective evidence of cardiac dysfunction (at rest)
   and

3. Response to treatment directed towards heart failure (in cases where the diagnosis is in doubt)

Criteria 1 and 2 should be fulfilled in all cases.

**Limitations of HF case finding**

To obtain an exhaustive picture regarding HF, which does not necessarily require routine hospitalisation, review of GP records or ad hoc surveys are necessary.

In HDRs, HF can be found under different diagnoses. Therefore if validation studies on HF are carried out these codes should be taken into account:

- heart failure: ICD-9 428, ICD-10 I50
- hypertensive heart disease: ICD-9 402, ICD-10 I11
- other primary cardiomyopathies: ICD-9 425.4, ICD-10 I42.5, I42.8
- alcoholic cardiomyopathy: ICD-9 425.5, ICD-10 I42.6
- secondary cardiomyopathy, unspecified: ICD-9 425.9, ICD-10 I42.9
- chronic cor pulmonale: ICD-9 416.9, ICD-10 27.9
10.3.e STROKE

**WHO criteria** 72

The recommended WHO stroke definition is a focal (or at times global) neurological impairment of sudden onset, and lasting more than 24 hours (or leading to death) and of presumed vascular origin. This definition includes spontaneous subarachnoid haemorrhage, but excludes subdural and extradural haematomas and TIA.

A careful review of the patient’s history is required to differentiate a previous stroke from previous TIA, as the two episodes may be misclassified.

This definition is normally used in longitudinal studies 73. When possible, incidence studies should register TIA because mild strokes are often misdiagnosed as TIA 74.

**MONICA criteria** 75

Definite stroke is a rapid development of focal signs (or global) or disturbance of cerebrovascular function lasting more than 24 hours (unless interrupted by surgery or death), with no apparent cause other than that of vascular origin; this category includes patients presenting clinical signs and symptoms suggestive of subarachnoid haemorrhage, intracerebral haemorrhage, or cerebral ischaemic infarct. The term “global” refers to patients with subarachnoid haemorrhage or deep coma but it excludes coma of systemic vascular origin such as shock, Stokes-Adams syndrome or hypertensive encephalopathy.

This definition of stroke includes reference to a focal or global disturbance of the cerebral function. One or more of the following definite focal signs must be present to make a diagnosis of stroke: unilateral or bilateral motor impairment (including uncoordination), unilateral or bilateral sensory impairment, aphasia/dysphasia (non-fluent speech), hemianopia (half-sided impairment of visual fields), diplopia, forced gaze (conjugate deviation), apraxia of acute onset, ataxia of acute onset (muscular uncoordination), perception deficit of acute onset.

Time dimension has to be met and the signs should have developed from a presumed vascular origin.

*Limitations of stroke case finding*

The above criteria were developed to allow comparisons of stroke rates in communities with different availability of diagnostic image technologies (CT and MRI) necessary for stroke type definition (ischemic and hemorrhagic).
11. **Recommended indicators**

Despite efforts to develop homogeneity, internationally standardised statistics still remain a goal to be achieved. The definition of disease differs from country to country, sometimes only slightly but sometimes more fundamentally, and it varies over time.

With the aim of improving future monitoring of CVD morbidity in Europe, indicators have been divided into 3 categories: already available indicators; those that should be implemented in the short-term; and those recommended for long-term implementation. Some countries have already implemented data collection for all three categories of indicators. For those that have not, **stepwise implementation is strongly recommended**, with development of adequate systems for collecting the short term indicators prior to proceeding with systems for collection and validation of the long-term indicators.

**Available indicators** are indicators which are simple and already available in almost all countries of the EU, for example, hospital discharge rates or mortality figures. Usually, these indicators are available for an entire country.

Under **short-term implementation** we list indicators which build on the available indicators but offer a more exhaustive and desirable overview of CVDs. The data derive from a variety of currently available sources but require a further level of processing to ensure accuracy. The data can be collected in samples representative of the population or in representative areas of the countries. Registers, which have already been implemented in many countries, represent an important source of this type of indicator (e.g. attack rates and incidence). Other available sources for indicators in this category include data collection systems that can be used to obtain indirect estimates of frequency of CVDs. Examples of this group are medication use, data sets which can be used as a proxy for burden of diseases and public health expenditures. It should be noted that, due to the ongoing evolution of treatment strategies over time and the appearance of new drugs, their consumption is not dealt with in detail in the current document.

Under **long-term implementation**, we list indicators which will require more time and more resources to be operational. Most of these indicators represent validated versions of the available and short term indicators in which medical records are carefully reviewed by expert epidemiologists using standardised diagnostic criteria. Long-term indicators would be collected in addition to available and short-term indicators. In order to develop and validate long-term these indicators it is highly recommended that each country invest in dedicated population epidemiology. As reported in
chapter 8, validation can be carried out in all or in a sample of suspected cases; the choice will depend on factors such as the type and the frequency of the disease and the precision desired. Five final tables (tables 13–19) summarise the common set of recommended indicators for each nosographic group.

For each health status and health system indicator we provide its operational and ICD nosographic definition, and describe the appropriate data sources. All indicators should be provided for both sexes together and separately for men and women, and for all ages together and for age-specific groups. Indicators should be reported as absolute numbers and as crude population rates. Recommended age groups for monitoring morbidity are decennia. It is particularly important to present data for the age ranges 35-44 years, 45-54 years, 55-64 years, 65-74 years, 75-84 years, 85 years and over. To ensure comparability between different countries, indicators should be directly standardised by age and sex using the European population as a reference.

11.1 ACUTE MYOCARDIAL INFARCTION (Table 13)

Following recommendations issued by the WHO and MONICA Project, AMI was defined by a combination of symptoms, enzyme and ECG patterns. With their high sensitivity, technology advances (serologic biomarkers and imaging techniques) allow the identification of very small infarcts that would not have been considered an AMI adopting WHO or MONICA criteria. With the new diagnostic criteria, any amount of myocardial necrosis caused by ischaemia is labelled as an infarct, so an individual who was formerly diagnosed as having severe stable or unstable angina pectoris might be diagnosed today as having had a MI.

The adoption of the new criteria may lead to a separate treatment of AMI and ACS. Therefore, as available they are considered jointly, but as short-term implementation and long-term implementation they will be distinct.

11.1.a Available indicators

<table>
<thead>
<tr>
<th>Indicator</th>
<th>mortality rate – health status: mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operational definition</td>
<td>annual AMI deaths per 100,000 population</td>
</tr>
<tr>
<td>ICD codes</td>
<td>ICD-9 410-414</td>
</tr>
<tr>
<td></td>
<td>ICD-10 I20-I25</td>
</tr>
</tbody>
</table>
**Data source** vital statistics

**Indicator** **hospital discharge rate** - *health status: morbidity*
**Operational definition** annual AMI hospitalisations per 100,000 population
**ICD codes** ICD-9 410
ICD-10 I21, I22
**Data source** hospital discharge records (main diagnosis)

**Indicator** **in-hospital case-fatality** - *health status: morbidity*
**Operational definition** annual proportion of deaths among AMI hospitalisations
**ICD codes** ICD-9 410
ICD-10 I21, I22
**Data source** hospital discharge records

**Indicator** **aggregate bed-day rate** – *health system: health care utilisation*
**Operational definition** sum of days in one year spent in hospital for AMI per 100,000 population
**ICD codes** ICD-9 410
ICD-10 I21, I22
**Data source** hospital discharge records

**Indicator** **mean length of stay** – *health system: health care utilisation*
**Operational definition** mean number of days spent in hospital per patient with AMI
**ICD codes** ICD-9 410
ICD-10 I21, I22
**Data source** hospital discharge records

11.1.b Short-term implementation

**Indicator** **mortality rate** – *health status: mortality*
**Operational definition** annual AMI deaths from per 100,000 population
**ICD codes** ICD-9 410
ICD-10 I21-I22
**Data source** vital statistics
**Indicator** attack rate/incidence rate - health status: morbidity/mortality

**Operational definition** annual AMI events (first and recurrent) per 100,000 population

**ICD codes** - non-fatal AMI events (ICD-9 410, ICD-10 I21-I22 from HDRs-main diagnosis) and
- coronary deaths (ICD-9 410-414, ICD-10 I20-I25 from mortality-underlying cause). Events less or equal 28 days apart are counted only once.

**Data source** population-based AMI register, record linkages between HDRs and death records (figure 1)

**Indicator** 1-day, 28-day case-fatality - health status: morbidity

**Operational definition** proportion of fatal AMI within the specified period of time

**ICD codes** non-fatal AMI and coronary deaths (ICD-9 410, ICD-10 I21-I22 from HDRs and ICD-9 410-414, ICD-10 I20-I25 from mortality)

**Data source** population-based AMI registers

**Indicator** thrombolytic therapy - health system: health care utilisation

**Operational definition** proportion of AMI patients treated with thrombolytic therapy

**ICD codes** ICD-9-CM 99.10 (injection or infusion of thrombolytic agent)

**Data source** population-based AMI registers

**Indicator** median length of stay – health system: health care utilisation

**Operational definition** median number of days spent in hospital per patient with AMI

**ICD codes** ICD-9 410
ICD-10 I21, I22

**Data source** hospital discharge records

**11.1.c Long-term implementation**

It is suggested to validate a sample of hospital discharge and mortality records using medical records and adopting diagnostic criteria described in paragraph 10.3. This will allow to estimate the sensitivity and specificity of hospital discharge diagnoses and mortality causes for AMI (see chapter 8).

**Indicator** validated mortality rate – health status: mortality

**Operational definition** validated AMI annual deaths per 100,000 population

**ICD codes** ICD-9 410-414
ICD-10 I20-I25
Data source: vital statistics, medical records

**Indicator**: validated attack rate/incidence rate - health status: morbidity/mortality

**Operational definition**: validated annual first (and recurrent) AMI per 100,000 population

**ICD codes**: first non-fatal AMI (ICD-9 410, ICD-10 I21-I22) and coronary deaths (ICD-9 410-414, ICD-10 I20-I25)

**Data source**: - population-based AMI registers, record linkage between HDRs and death records by a unique ID
- cohort longitudinal studies
- medical records

**Indicator**: re-admission after 1 year - health status: morbidity

**Operational definition**: re-admission one year following initial admission for AMI due to re-infarction, IHD, HF and all causes

**ICD codes**: AMI: ICD-9 410, ICD-10 I21-I22
IHD: ICD-9 410-414, ICD-10 I20-I25
HF: ICD-9 428, ICD-10 I50

**Data source**: population-based AMI register

**Indicator**: 1 year survival - health status: morbidity

**Operational definition**: proportion of patients who survived a non-fatal AMI, who are alive after 1 year

**ICD codes**: non-fatal AMI (ICD-9 410, ICD-10 I21-I22) and coronary deaths (ICD-9 410-414, ICD-10 I20-I25)

**Data source**: population-based AMI registers, population cohort studies

**Indicator**: 28-day case-fatality among first day survivors - health status: morbidity

**Operational definition**: proportion of fatal AMI within the specified period of time

**ICD codes**: non-fatal AMI and coronary deaths (ICD-9 410, ICD-10 I21-I22 from HDRs and ICD-9 410-414, ICD-10 I20-I25 from mortality)

**Data source**: population-based AMI registers

**Indicator**: CABG per AMI – health system: health care utilisation

**Operational definition**: proportion of AMI patients who have received a CABG up to 90 days following the initial admission for AMI

**ICD codes**: CABG: ICD-9-CM 36.1; NOMESCO: FNA-FNE
AMI: ICD-9 410, ICD-10 I21-I22

**Data source**

population-based AMI register linked with hospital discharge records or procedure register

**Indicator**  
**PTCA per AMI** – *health system: health care utilisation*

**Operational definition**

proportion of AMI patients who have received a PTCA up to 90 days following the initial admission for AMI

**ICD codes**

PTCA: ICD-9-CM 36.01, 36.02, 36.05, 36.06 (stent); NOMESCO: FNG0

AMI: ICD-9 410, ICD-10 I21-I22

**Data source**

population-based AMI register linked with hospital discharge records or procedure register

**Indicator**  
**emergency CABG (within 24 hrs) rate** – *health system: health care utilisation*

**Operational definition**

proportion of CABG performed within 24 hours from the onset of the AMI

**ICD codes**

ICD-9-CM 36.1; NOMESCO: FNA-FNE

**Data source**

- hospital discharge records
- population-based AMI and procedure registers

**Indicator**  
**emergency PTCA (within 24 hrs) rate** – *health system: health care utilisation*

**Operational definition**

proportion of PTCA performed within 24 hours from the onset of the AMI

**ICD codes**

PTCA: ICD-9-CM 36.01, 36.02, 36.05, 36.06 (stent);
NOMESCO: FNG0

**Data source**

- hospital discharge records
- population-based AMI and procedure registers

**Indicator**  
**30-day case-fatality for CABG** – *health system: health care utilisation*

**Operational definition**

30-day case fatality of hospital discharges of CABG

**ICD codes**

ICD-9-CM 36.1; NOMESCO: FNA-FNE

**Data source**

linkage between hospital discharge records for CABG and mortality
11.2 ACUTE CORONARY SYNDROMES

11.2.a Short-term implementation

**Indicator** mortality rate – health status: mortality
**Operational definition** annual ACS deaths per 100,000 population
**ICD codes** ICD-9 410, 411
ICD-10 I20.0, I21, I22
**Data source** vital statistics

**Indicator** hospital discharge rate - health status: morbidity
**Operational definition** annual ACS hospitalisations per 100,000 population
**ICD codes** ICD-9 410, 411
ICD-10 I20.0, I21, I22
**Data source** hospital discharge records

**Indicator** aggregate bed-day rate – health system: health care utilisation
**Operational definition** sum of days in one year spent in hospital for ACS per 100,000 population
**ICD codes** ICD-9 410, 411
ICD-10 I20.0, I21, I22
**Data source** hospital discharge records

**Indicator** mean length of stay – health system: health care utilisation
**Operational definition** mean number of days spent in hospital per patient with ACS
**ICD codes** ICD-9 410, 411
ICD-10 I20.0, I21, I22
**Data source** hospital discharge records

11.2.b Long-term implementation

It is suggested to validate a sample of hospital discharge and mortality records using medical records and adopting diagnostic criteria described in paragraph 10.3. This will allow to estimate the sensitivity and specificity of hospital discharge diagnoses and mortality for ACS (see chapter 8).

**Indicator** validated mortality rate – health status: mortality
**Operational definition** validated annual deaths of ACS per 100,000 population
**ICD codes** ICD-9 410, 411
ICD-10 I20.0, I21, I22
Data source: vital statistics

Indicator: **validated attack rate/incidence rate** - health status: morbidity/mortality

Operational definition: annual ACS (first and recurrent) per 100,000 population

ICD codes: non-fatal ACS (ICD-9 410, 411; ICD-10 I20.0, I21, I22) and coronary deaths (ICD-9 410–414; ICD-10 I20-I25)

Data source: population-based ACS registers, record linkage between HDRs and death records by a unique ID; medical records

---

Indicator: **CABG per ACS** – health system: health care utilisation

Operational definition: proportion of ACS patients who have received a CABG up to 90 days following the initial admission for ACS

ICD codes: CABG: ICD-9-CM 36.1; NOMESCO: FNA-FNE
ACS: ICD-9 410, 411, 413, ICD-10 I20.0, I21, I22, I24

Data source: population-based AMI register linked with hospital discharge records or procedure register

---

Indicator: **PTCA per ACS** – health system: health care utilisation

Operational definition: proportion of ACS patients who have received a PTCA up to 90 days following the initial admission for ACS

ICD codes: PTCA: ICD-9-CM 36.01, 36.02, 36.05, 36.06 (stent) NOMESCO: FNG0
ACS: ICD-9 410, 411, 413, ICD-10 I20.0, I21, I22, I24;

Data source: population-based ACS register linked with hospital discharge records or procedure register

---

Indicator: **emergency CABG (within 24 hrs) rate** – health system: health care utilisation

Operational definition: proportion of CABG performed within 24 hours from the onset of the ACS event

ICD codes: ICD-9-CM 36.1

Data source: population-based ACS and procedure registers
**Indicator** emergency PTCA (within 24 hrs) rate – health system: health care utilisation

**Operational definition** proportion of PTCA performed within 24 hours from the onset of the ACS event

**ICD codes** PTCA: ICD-9-CM 36.01, 36.02, 36.05, 36.06 (stent)

**Data source** population-based ACS and procedure registers

**Indicator** median length of stay – health system: health care utilisation

**Operational definition** median number of days spent in hospital per patient with ACS

**ICD codes** ICD-9 410, 411
ICD-10 I20.0, I21, I22

**Data source** hospital discharge records

**Indicator** ACS patients in ICU – health system: health care utilisation

**Operational definition** percentage of ACS patients admitted in Intensive Care Units (ICU) per year

**ICD codes** ICD-9 410, 411
ICD-10 I20.0, I21, I22

**Data source** population-based ACS register

### 11.3 ALL ISCHAEMIC HEART DISEASES

#### 11.3.a Available indicators

**Indicator** mortality rate – health status: mortality

**Operational definition** annual deaths from IHS per 100,000 population

**ICD codes** ICD-9 410 - 414
ICD-10 I20 - I25

**Data source** vital statistics

**Indicator** hospital discharge rate - health status: morbidity

**Operational definition** annual IHD hospitalisations per 100,000 population

**ICD codes** ICD-9 410 - 414
ICD-10 I20 - I25
11.3.b Short-term implementation

**Data source** hospital discharge records

**Indicator** mortality rate – health status: mortality

**Operational definition** annual deaths from HIS and SD per 100,000 population

**ICD codes** ICD-9 410 - 414, 798  
ICD-10 I20 - I25, R96, R98

**Data source** vital statistics

**Indicator** prevalence of effort angina - health status: morbidity

**Operational definition** number of subjects who have experienced typical angina per 100,000 population

**ICD codes** ICD-9 413  
ICD-10 I20

**Data source** HES and CVD surveys which include the LSHTM questionnaire

**Indicator** CABG rate – health system: health care utilisation

**Operational definition** annual CABG hospitalisations per 100,000 population

**ICD codes** ICD-9-CM 36.1  
NOMESCO: FNA-FNE

**Data source** hospital discharge records

**Indicator** PTCA rate – health system: health care utilisation

**Operational definition** annual PTCA hospitalisations per 100,000 population

**ICD codes** ICD-9-CM 36.01, 36.02, 36.05, 36.06 (stent)

**Data source** hospital discharge records, NOMESCO: FNG0

**Indicator** coronary angiography rate – health system: health care utilisation

**Operational definition** annual number of coronary angiographies per 100,000 population

**ICD codes** ICD-9-CM 88.55-88.57

**Data source** hospital discharge records
11.3.c Long-term implementation

**Indicator** prevalence of IHD - health status: morbidity

**Operational definition** number of subjects who have experienced IHD (myocardial infarction AND/OR by-pass AND/OR PTCA AND/OR angina) per 100,000 population

**ICD codes**
in the first hospital discharge diagnosis:
- IHD: ICD-9 410-414, ICD-10 I20-I25
- CABG: ICD-9-CM 36.1; NOMESCO FNA-FNE
- PTCA: ICD-9-CM 36.01, 36.02, 36.05, 36.06 (stent); NOMESCO FNG0

**Data source**
- HES which include the LSHTM questionnaire, questions on re-vascularisation procedures, ECG (Minnesota code) and physician diagnoses
- linkage between specific registers (AMI, CABG, PTCA) and mortality

**Indicator** functional disability and quality of life - health status: disability

**Operational definition** proportion of patients affected by IHD impaired in ADL or positive to EuroQol questionnaire

**Data source**
HES or CVD surveys which include the ADL questionnaire or the EuroQol questionnaire

11.4 HEART FAILURE
11.4.a Available indicators

Currently no specific indicators for HF are available directly from routine health statistics. However data exist for mortality and hospital discharge records at a national level. To obtain routine HF indicators for each country is only a matter of reporting existing routine data in different formats.

**Indicator** heart transplant rate - health system: health care utilisation

**Operational definition** annual heart transplant hospitalisations per 100,000 population

**ICD codes** ICD-9-CM 37.5

**Data source** hospital discharge records
11.4.b Short-term implementation

**Indicator**
- **mortality rate** - *health status: mortality*

**Operational definition**
annual HF deaths per 100,000 population

**ICD codes**
- ICD-9 428
- ICD-10 I50

**Data source**
vital statistics

**Indicator**
- **hospital discharge rate** - *health status: morbidity*

**Operational definition**
annual HF hospitalisations per 100,000 population

**ICD codes**
- ICD-9 428
- ICD-10 I50

**Data source**
hospital discharge records

**Indicator**
- **aggregate bed-day rate** – *health system: health care utilisation*

**Operational definition**
annual sum of number of days spent in hospital for HF per 100,000 population

**ICD codes**
- ICD-9 428
- ICD-10 I50

**Data source**
hospital discharge records

**Indicator**
- **mean length of stay** – *health system: health care utilisation*

**Operational definition**
mean number of days spent in hospital per HF patient

**ICD codes**
- ICD-9 428
- ICD-10 I50

**Data source**
hospital discharge records

11.4.c Long-term implementation

It is suggested to validate a sample of hospital discharge and mortality records using medical records and adopting diagnostic criteria described in paragraph 10.3. This will allow to estimate the sensitivity and specificity of hospital discharge diagnoses and mortality causes for HF (see chapter 8).

**Indicator**
- **validated mortality rate** - *health status: mortality*

**Operational definition**
validated annual deaths from HF per 100,000 population in the following causes of death: heart failure, hypertensive heart disease, other primary cardiomyopathies, alcoholic cardiomyopathy, secondary cardiomyopathy, chronic cor pulmonale
**ICD codes**

- **ICD-9**: 428.0, 428.1, 428.9, 402, 416, 425.4, 425.5, 425.9
- **ICD-10**: I27.9, I50, I11, I42.5, I42.8, I42.6, I42.9

**Data source**

- vital statistics
- medical records

**Indicator**

**validated hospital discharge rate** - health status: morbidity

**Operational definition**

validated annual HF hospitalisations per 100,000 population in the following diagnoses: heart failure, hypertensive heart disease, other primary cardomyopathies, alcoholic cardomyopathy, secondary cardomyopathy, chronic cor pulmonale

**ICD codes**

- **ICD-9**: 428.0, 428.1, 428.9, 402, 416, 425.4, 425.5, 425.9
- **ICD-10**: I27.9, I50, I11, I42.5, I42.8, I42.6, I42.9

**Data source**

hospital discharge records, medical records

**Indicator**

**attack rate/incidence rate of HF** - health status: morbidity/mortality

**Operational definition**

validated hospitalisations for symptomatic HF and HF deaths per 100,000 population

**ICD codes**

- non-fatal HF and HF deaths: ICD-9: 428.0, 428.1, 428.9, 402, 416, 425.4, 425.5, 425.9
- ICD-10: I27.9, I50, I11, I42.5, I42.8, I42.6, I42.9

**Data source**

disease registers, longitudinal cohort studies

**Indicator**

**prevalence of HF** - health status: morbidity

**Operational definition**

number of patients with HF per 100,000 population

**ICD codes**

- heart failure: based on Framingham or Boston or ESC criteria.

**Data source**

- HES surveys
- CVD surveys
- GP-network

**Indicator**

**median length of stay** – health system: health care utilisation

**Operational definition**

median number of days spent in hospital per patient

**ICD codes**

- **ICD-9**: 428
- **ICD-10**: 150

**Data source**

hospital discharge records
**Indicator**  
functional disability and quality of life - health status: disability

**Operational definition**  
proportion of patients affected by HF impaired in ADL or positive to EuroQol questionnaire

**Data source**  
HES or CVD surveys which include the ADL questionnaire or the EuroQol questionnaire

### 11.5 OTHER FORMS OF HEART DISEASES

#### 11.5.a Available indicators

<table>
<thead>
<tr>
<th>Indicator</th>
<th>mortality rate – health status: mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operational definition</strong></td>
<td>annual deaths per 100,000 for the following causes: rheumatic heart disease, hypertensive disease, other forms of heart diseases</td>
</tr>
</tbody>
</table>
| **ICD codes** | ICD-9: 393-398, 401-405, 420-429  
ICD-10: I05-I09, I11-I13, I30-I49, I51 |
| **Data source** | vital statistics |

<table>
<thead>
<tr>
<th>Indicator</th>
<th>hospital discharge rate - health status: morbidity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
<td>annual hospitalisations per 100,000 population for the following diagnoses: rheumatic heart disease, hypertensive disease, other forms of heart diseases</td>
</tr>
</tbody>
</table>
| **ICD codes** | ICD-9: 393-398, 401-405, 420-429  
ICD-10: I05-I09, I11-I13, I30-I49, I51 |
| **Data source** | hospital discharge records |

<table>
<thead>
<tr>
<th>Indicator</th>
<th>mean length of stay – health system: health care utilisation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operational definition</strong></td>
<td>mean number of days spent in hospital per patient</td>
</tr>
</tbody>
</table>
| **ICD codes** | ICD-9: 393-398, 401-405, 420-429  
ICD-10: I05-I09, I11-I13, I30-I49, I51 |
| **Data source** | hospital discharge records |

<table>
<thead>
<tr>
<th>Indicator</th>
<th>aggregate bed-day rate – health system: health care utilisation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operational definition</strong></td>
<td>sum of days in one year spent in hospital for other forms of heart diseases (rheumatic heart disease, hypertensive disease, other forms of heart diseases) per 100,000 population</td>
</tr>
</tbody>
</table>
| **ICD codes** | ICD-9: 393-398, 401-405, 420-429  
ICD-10: I05-I09, I11-I13, I30-I49, I51 |
| **Data source** | hospital discharge records |
11.5.b Short-term implementation

Indicator: mortality rate – health status: mortality
Operational definition: annual deaths per 100,000 for the following causes: atherosclerosis, aortic aneurisms, acute cor pulmonale, dysrhythmias, acute pulmonary oedema
ICD codes: ICD-9: 440, 441, 444, 415, 426-427, 428, 429
ICD-10: I70, I71, I82, I44-I49, I50, I51
Data source: vital statistics

Indicator: hospital discharge rate – health status: morbidity
Operational definition: annual hospitalisations per 100,000 for the following causes: atherosclerosis, aortic aneurisms, acute cor pulmonale, dysrhythmias, acute pulmonary oedema
ICD codes: ICD-9: 440, 441, 444, 415, 426-427, 428, 429
ICD-10: I70, I71, I82, I44-I49, I50, I51
Data source: hospital discharge records

Indicator: mean length of stay – health system: health care utilisation
Operational definition: mean number of days spent in hospital per patient
ICD codes: ICD-9: 440, 441, 444, 415, 426-427, 428, 429
ICD-10: I70, I71, I82, I44-I49, I50, I51
Data source: hospital discharge records

Indicator: aggregate bed-day rate – health system: health care utilisation
Operational definition: number of days spent in hospital for other forms of heart diseases (atherosclerosis, aortic aneurisms, acute cor pulmonale, dysrhythmias, acute pulmonary oedema) per 100,000 population
ICD codes: ICD-9: 440, 441, 444, 415, 426-427, 428, 429
ICD-10: I70, I71, I82, I44-I49, I50, I51
Data source: hospital discharge records

Indicator: hospital discharge rate for surgical operations and invasive procedures - health system: health care utilisation
Operational definition: annual hospitalisation for valvular operations, aortic aneurism operations, other aneurism operations, pace makers, implantable cardioverter defibrillators, catheter ablation per 100,000 population
ICD codes: - valvular: ICD-9-CM 35.0-35.3, 35.95, 35.96, 35.99
- pacemaker: ICD-9-CM 00.50, 37.7-37.8, 39.64, 39.8, 89.4
- catheter ablation: ICD-9-CM 37.34
- implantable cardioverter defibrillators: ICD-9-CM 37.94, 00.51

Data source: hospital discharge records

11.5.c Long-term implementation

Indicator: validated mortality rate – health status: mortality

Operational definition: validated annual deaths per 100,000 for the following causes: rheumatic heart disease, hypertensive disease, other forms of heart diseases, atherosclerosis, aortic aneurisms, acute cor pulmonale, dysrhythmias, acute pulmonary oedema

ICD codes:
- ICD-9: 393-398, 401-405, 420-429, 440, 441, 444, 415, 426-427, 428, 429

Data source: vital statistics, medical records

Indicator: validated hospital discharge rate – health status: morbidity

Operational definition: validated annual hospitalisations per 100,000 for the following causes: rheumatic heart disease, hypertensive disease, other forms of heart diseases, atherosclerosis, aortic aneurisms, acute cor pulmonale, dysrhythmias, acute pulmonary oedema

ICD codes:
- ICD-9: 393-398, 401-405, 420-429, 440, 441, 444, 415, 426-427, 428, 429
- ICD-10: I05-I09, I11-I13, I30-I49, I51, I70, I71, I82, I44-I49, I50

Data source: Hospital discharge and medical records

Indicator: median length of stay – health system: health care utilisation

Operational definition: median number of days spent in hospital per patient

ICD codes:
- ICD-9: 393-398, 401-405, 420-429, 440, 441, 444, 415, 426-427, 428, 429
- ICD-10: I05-I09, I11-I13, I30-I49, I51, I70, I71, I82, I44-I49, I50

Data source: hospital discharge records

11.6 CEREBROVASCULAR DISEASES AND VASCULAR DEMENTIA

11.6.a Available indicators
<table>
<thead>
<tr>
<th>Indicator</th>
<th><strong>cerebrovascular mortality rate</strong> – health status: mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operational definition</td>
<td>annual deaths from cerebrovascular diseases per 100,000 population</td>
</tr>
</tbody>
</table>
| ICD codes | ICD-9 430 - 438  
ICD-10 I60 - I69, G45 |
| Data source | vital statistics |

<table>
<thead>
<tr>
<th>Indicator</th>
<th><strong>dementia mortality rate</strong> – health status: mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operational definition</td>
<td>annual deaths from dementia per 100,000 population</td>
</tr>
</tbody>
</table>
| ICD codes | ICD-9 290.4  
ICD-10 F01 |
| Data source | vital statistics |

<table>
<thead>
<tr>
<th>Indicator</th>
<th><strong>cerebrovascular hospital discharge rate</strong> - health status: morbidity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operational definition</td>
<td>annual hospitalisations for cerebrovascular diseases per 100,000 population</td>
</tr>
</tbody>
</table>
| ICD codes | ICD-9 430 – 438  
ICD-10 I60 - I69, G45 |
| Data source | hospital discharge records |

<table>
<thead>
<tr>
<th>Indicator</th>
<th><strong>dementia hospital discharge rate</strong> - health status: morbidity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operational definition</td>
<td>annual hospitalisations for dementia per 100,000 population</td>
</tr>
</tbody>
</table>
| ICD codes | ICD-9 290.4  
ICD-10 F01 |
| Data source | hospital discharge records |

<table>
<thead>
<tr>
<th>Indicator</th>
<th><strong>aggregate bed-day rate</strong> – health system: health care utilisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operational definition</td>
<td>sum of days in one year spent in hospital for stroke</td>
</tr>
</tbody>
</table>
| ICD codes | ICD-9 430-438  
ICD-10 I60 - I69, G45 |
| Data source | hospital discharge records |

<table>
<thead>
<tr>
<th>Indicator</th>
<th><strong>mean length of stay</strong> – health system: health care utilisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operational definition</td>
<td>mean number of days spent in hospital per patient</td>
</tr>
</tbody>
</table>
| ICD codes | ICD-9 430-438  
ICD-10 I60-I69, G45 |
| Data source | hospital discharge records |
### Indicator: Carotid Angioplasty Rate - Health System: Health Care Utilisation

**Operational Definition:**
Annual procedures of carotid angioplasty per 100,000 population age 40 years and over.

**ICD codes:**
ICD-9-CM 39.50 NOMESCO: XAC85 (Denmark)

**Data Source:**
Hospital discharge records

### Indicator: Mortality Rate - Health Status: Mortality

**Operational Definition:**
Annual deaths from ischaemic stroke, subarachnoid haemorrhage, intracerebral haemorrhage, unspecified stroke per 100,000 population.

**ICD codes:**
- Occlusion, stenosis and thrombosis of cerebral arteries: ICD-9 434; ICD-10 I66, I63
- Subarachnoid haemorrhage: ICD-9 430, ICD-10 I60
- Intracerebral haemorrhage: ICD-9 431, 432, ICD-10 I61, I62
- Unspecified stroke: ICD-9 436-437; ICD-10 I64, I67, I68

**Data Source:**
Vital statistics

### Indicator: Hospital Discharge Rate - Health Status: Morbidity

**Operational Definition:**
Annual hospitalisations for ischaemic stroke, subarachnoid haemorrhage, intracerebral haemorrhage, unspecified stroke per 100,000 population.

**ICD codes:**
- Occlusion, stenosis and thrombosis of cerebral arteries: ICD-9 434; ICD-10 I66, I63
- Subarachnoid haemorrhage: ICD-9 430, ICD-10 I60
- Intracerebral haemorrhage: ICD-9 431, 432, ICD-10 I61, I62
- Unspecified acute stroke: ICD-9 436; ICD-10 I64

**Data Source:**
Hospital discharge records

### Indicator: Attack Rate/Incidence Rate - Health Status: Morbidity

**Operational Definition:**
Annual stroke events (first and recurrent) per 100,000 population.

**ICD codes:**
Fatal and non-fatal: ICD-9 430-438
ICD-10 I60-I69, G45

**Data Source:**
HDRs linked with mortality

### Indicator: 7-Day Case-Fatality Rate - Health Status: Morbidity

**Operational Definition:**
The proportion of ischaemic and haemorrhagic (subarachnoidal and intracerebral) stroke events that are fatal within 7 days from the onset.

**ICD codes:**
Fatal and non-fatal: ICD-9 430-438
ICD-10 I60-I69, G45

**Data source**
- HDRs linked with mortality

**Indicator**
**brain imaging per population** – health system: health care utilisation

**Operational definition**
number of CT-scans (Computerized axial Tomography of head) and MRI (Magnetic Resonance Imaging of brain and brainstem) per 100,000 population

**ICD codes**
CT-scan: ICD-9-CM 87.03
MRI: ICD-9CM 88.91

**Data source**
hospital discharge records

**Indicator**
**mean length of stay for cerebrovascular diseases** – health system: health care utilisation

**Operational definition**
mean or median number of days spent in hospital per patient

**ICD codes**
ICD-9 430-438
ICD-10 I60-I69, G45

**Data source**
hospital discharge records

### 11.6.c Long-term implementation

It is suggested to validate a sample of hospital discharge and mortality records using medical records and adopting diagnostic criteria described in paragraph 10.3. This will allow to estimate the sensitivity and specificity of hospital discharge diagnoses and mortality causes for cerebrovascular accidents (see chapter 8).

**Indicator**
**validated attack rate/incidence by subtype of stroke** – health status: morbidity

**Operational definition**
validated annual subtype (ischaemic, subarachnoidal haemorrhage, intracerebral haemorrhage) of stroke events (first or recurrent) per 100,000 population

**ICD codes**
non-fatal:
- occlusion and stenosis of cerebral arteries and cerebral infarction: ICD-9 434, 436; ICD-10 I66; I63, I64
- subarachnoid haemorrhage: ICD-9 430, ICD-10 I60
- intracerebral haemorrhage and other non-traumatic intracranial: ICD-9 431-432, ICD-10 I61-I62
- unspecified acute stroke: ICD-9 436, ICD-10 I64

fatal: ICD-9 430-438
ICD-10 I60-I69, G45
Data source: population-based stroke registers, cohort longitudinal studies if population acute stroke registers unavailable, medical records

Indicator: prevalence of stroke - health status: morbidity
Definition: number of subjects who survived a cerebrovascular event per 100,000 population
ICD codes:
- occlusion, stenosis, thrombosis of cerebral arteries and not specified: ICD-9 434, 436; ICD-10 I66, I64
- subarachnoid haemorrhage: ICD-9 430; ICD-10 I60
- intracerebral haemorrhage and other non-traumatic intracranial: ICD-9 431-432; ICD-10 I61-I62
Data source:
- CVD surveys, HIS and HES, ad hoc elderly HES.
- prevalence can be derived from other indicators: incidence (I) and duration (D) of CVA as follows: \( P = I \times D \)
- population registers: prevalence can be calculated if there is a long period of registration and there is information on incidence and survival (\( P = I \times S \))

Indicator: stroke units per population - health system: health care utilisation
Operational definition: number of stroke units per 100,000 population (A stroke unit is a pool of dedicated human and technological resources used in the treatment of stroke)
Data source: Ministry of Health

Indicator: functional disability and quality of life - health status: disability
Operational definition: proportion of patients affected by stroke impaired in ADL or positive to EuroQol questionnaire
Data source: HES or CVD surveys which include the ADL questionnaire or the EuroQol questionnaire; ad hoc surveys at 1 year follow-up of stroke patients

11.7 MEDICINE USE FOR CARDIOVASCULAR DISEASES AND THEIR RISK FACTORS

Indicator: medication use - health system: health care utilisation
Definition: annual DDDs / 1000 inhabitants
ATC codes:
- antihypertensives C02
- diuretics C03
- beta blocking agents C07
- calcium channel blockers C08
- ACE inhibitors C09A, C09B
- nitrates C01DA
- statins C10AA
- fibrates C10AB
- acetylsalicylic acid (aspirine) B01AC
- antithrombotic agents, vitamin K antagonist B01AA
- antithrombotic agents, heparin group B01AB
- digitalis glycosides C01AA
- spironolactone C03DA01

Data source  
Ministry of Health, register of medicine consumption

Indicator  
**medicine use for patients with diagnosed IHD** - health system: health care utilisation

Operational definition  
proportion of patients with IHD using

ATC codes  
- beta blocking agents C07
- calcium channel blockers C08
- ACE inhibitors C09A, C09B
- nitrates C01DA
- acetylsalicylic acid (aspirine) B01AC
- statins C10AA

Data source  
CVD surveys

Indicator  
**proportion of patients using evidence-based drugs** - health system: health care utilisation

Operational definition  
proportion of stroke patients using:
- antithrombotic B01
- antiplatelet B01AC
- anticoagulant B01AA

Data source  
population-based stroke registers

**12. Conclusions**

The ultimate aim of this project was to prepare a list of recommended indicators to improve the information and knowledge needed for monitoring cardiovascular diseases of major importance and to contribute to the promotion of health and prevention throughout the European Union.

In addition to developing the lists of indicators, a major outcome of this project was the development of a spirit of collaboration among participating countries. The suggested
recommendations described in this final report have been developed through a close collaboration among the partner countries. They derive from the work we have undertaken to compile a detailed inventory of data sources already available in the different countries and the methods used by each country to collect them, from detailed discussions of proposed indicators and the best way of prioritising them, as well as how to maximise the use and quality of existing data. The collaboration developed as a result of the project will undoubtedly have long term positive implications for future CVD monitoring efforts in Europe.

A list of new indicators has been proposed. Some are based on available data and can be produced over a relatively short period of time: these we have called short-term implementation indicators. Others, which we have called long-term implementation indicators, need a longer period of time to be implemented, and require, for each country, the training of a dedicated team of epidemiologists to support their development. We have not included outcome and quality care indicators: these go beyond the scope of the project and are to be developed in the future.

Cardiovascular diseases are responsible for a great deal of hospitalisation and death. However to obtain a comprehensive picture of those diseases, many sources of information must be integrated. Clinical events may be acute or chronic and vary in their severity; hospitalisation may be for the first occurrence of a disease or for treatment of further episodes or sequelae. Validation of data thus becomes essential and the ability to temporally link events in time is of great potential interest. Following the experience of the Nordic countries, we therefore also recommend that all medical and death records across Europe adopt a personal identification number, which would allow an easier and more accurate record linkage among the different sources of information.

In summary, the project added value by:

- creating of a network of experts from each country to support the monitoring cardiovascular diseases across Europe;
- defining of a list of common indicators to be adopted by each country;
- underlining the need for each country to invest in a dedicated population epidemiology team to develop validated data sources which will allow cross national monitoring;
- establishing the basis for an improved future regulation in public health policies concerning the surveillance of cardiovascular diseases throughout European countries;
- proposing a stepwise procedure for the implementation of the recommended indicators.
The application of the recommended standard methodology in all countries will result in the availability of reliable, valid and therefore comparable data on CVD morbidity at the European level.
Figure 1: Data flow in a population-based register

- **Mortality Suspected Causes**
  - Cross-check with the mortality register
  - Death certificates with suspected causes
  - Fatal Event

- **Hospital Discharge Suspected Events**
  - Discharged before the 28th day
  - Alive at the 28th day
  - Non-fatal Event
  - Alive at the 28th day
  - Non-fatal Event
Table 1a – WHO: HFA - DB
"Morbidity" available years and source

<table>
<thead>
<tr>
<th>FIRST</th>
<th>LAST</th>
<th>SOURCES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate</td>
<td>Year</td>
<td>Rate</td>
</tr>
<tr>
<td>AUSTRIA</td>
<td>3087.2</td>
<td>1989</td>
</tr>
<tr>
<td>BELGIUM</td>
<td>1766.8</td>
<td>1992</td>
</tr>
<tr>
<td>FINLAND</td>
<td>3259.5</td>
<td>1987</td>
</tr>
<tr>
<td>FRANCE</td>
<td>2219.1</td>
<td>1993</td>
</tr>
<tr>
<td>GERMANY</td>
<td>2629.2</td>
<td>1993</td>
</tr>
<tr>
<td>GREECE</td>
<td>2115.0</td>
<td>1997</td>
</tr>
<tr>
<td>IRELAND</td>
<td>1414.9</td>
<td>1994</td>
</tr>
<tr>
<td>ITALY</td>
<td>1807.5</td>
<td>1982</td>
</tr>
<tr>
<td>LUXEMBOURG</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>NETHERLANDS</td>
<td>1419.7</td>
<td>1990</td>
</tr>
<tr>
<td>NORWAY</td>
<td>1992.1</td>
<td>1991</td>
</tr>
<tr>
<td>PORTUGAL</td>
<td>721.8</td>
<td>1991</td>
</tr>
<tr>
<td>SPAIN</td>
<td>675.9</td>
<td>1986</td>
</tr>
<tr>
<td>SWEDEN</td>
<td>2815.3</td>
<td>1987</td>
</tr>
<tr>
<td>UNITED KINGDOM</td>
<td>1092.5</td>
<td>1980</td>
</tr>
<tr>
<td>EU average</td>
<td>2017.8</td>
<td>1991</td>
</tr>
</tbody>
</table>
### Table 1b - WHO: HFA - DB
"Hospital discharges: ischaemic heart disease / 100 000" available years and source

<table>
<thead>
<tr>
<th></th>
<th>Rate</th>
<th>Year</th>
<th>Rate</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUSTRIA</td>
<td>723.1</td>
<td>1989</td>
<td>923.9</td>
<td>2000</td>
</tr>
<tr>
<td>BELGIUM</td>
<td>544.3</td>
<td>1992</td>
<td>777.6</td>
<td>1998</td>
</tr>
<tr>
<td>DENMARK</td>
<td>704.6</td>
<td>1987</td>
<td>829.2</td>
<td>2000</td>
</tr>
<tr>
<td>FINLAND</td>
<td>1094.1</td>
<td>1987</td>
<td>1139.8</td>
<td>2001</td>
</tr>
<tr>
<td>FRANCE</td>
<td>489.8</td>
<td>1993</td>
<td>488.3</td>
<td>2000</td>
</tr>
<tr>
<td>GERMANY</td>
<td>798.7</td>
<td>1993</td>
<td>1035.0</td>
<td>1999</td>
</tr>
<tr>
<td>GREECE</td>
<td>729.2</td>
<td>1997</td>
<td>738.5</td>
<td>1998</td>
</tr>
<tr>
<td>IRELAND</td>
<td>451.1</td>
<td>1994</td>
<td>495.5</td>
<td>2001</td>
</tr>
<tr>
<td>ITALY</td>
<td>343.8</td>
<td>1982</td>
<td>591.7</td>
<td>2000</td>
</tr>
<tr>
<td>LUXEMBOURG</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>NETHERLANDS</td>
<td>545.6</td>
<td>1990</td>
<td>511.8</td>
<td>2001</td>
</tr>
<tr>
<td>NORWAY</td>
<td>860.5</td>
<td>1991</td>
<td>946.0</td>
<td>2001</td>
</tr>
<tr>
<td>PORTUGAL</td>
<td>207.8</td>
<td>1994</td>
<td>280.8</td>
<td>2001</td>
</tr>
<tr>
<td>SPAIN</td>
<td>160.7</td>
<td>1986</td>
<td>312.5</td>
<td>1997</td>
</tr>
<tr>
<td>SWEDEN</td>
<td>866.1</td>
<td>1987</td>
<td>917.0</td>
<td>2001</td>
</tr>
<tr>
<td>UNITED KINGDOM</td>
<td>313.1</td>
<td>1980</td>
<td>544.5</td>
<td>1994</td>
</tr>
<tr>
<td><strong>EU average</strong></td>
<td><strong>586.2</strong></td>
<td><strong>1992</strong></td>
<td><strong>657.9</strong></td>
<td><strong>2000</strong></td>
</tr>
</tbody>
</table>

**SOURCES**

- **AUSTRIA**: Ministry of Social Affairs, Public Health and the Environment
- **BELGIUM**: National Patient Registry, Ministry of Health. January 2000: only patients discharged from public hospitals are included December 2002: From 1994 Denmark started using ICD-10
- **DENMARK**: Hospital Discharge Register, Stakes. From 1998 Stakes Care Register
- **FINLAND**: Federal Statistical Office, Hospital statistics - diagnostic data of the hospital patients
- **FRANCE**: Hospital in-Patient Enquiry; figures refer to discharges and not to individual people. Data from private, maternity or psychiatric hospitals are not included
- **GERMANY**: ISTAT-Data on discharges are obtained by a sample survey referred to discharges over the first week in each month of the year. Under the hypothesis of uniform distribution of discharges in the whole month, an estimation of annual discharges is obtained multiplying the sample data by a coefficient (4.35 = average number of weeks in a month); January 2001, Ministry of Health: information derives from S.D.O. (Scheda di Dimissione Ospedaliera) and refers to all public and private hospitals
- **GREECE**: Dutch Centre for Health Care Information: National Medical Registry
- **IRELAND**: November 2001: Only the acute hospitals that belong to the National Health Service (NHS) on the mainland are included. The data from the hospitals located in the autonomous regions of Azores and Madeira, and the private hospitals are not included
- **ITALY**: December 2001: Total number of patients discharged from all hospitals during the given calendar year with the principal diagnosis falling into the group of Chapter VII of ICD-9MC. Source: National Statistics Institute. Hospital Morbidity Survey
- **LUXEMBOURG**: ICD-9: 390-459. Source: Hospital Discharge Register, NBHW
- **NETHERLANDS**: January 2001: data refer to Great Britain only. Change of basis (definition) in 1998

**Eurostat**: National Eurostat offices.

**EU average**: Union of European Member States.
<table>
<thead>
<tr>
<th>Country</th>
<th>Rate</th>
<th>Year</th>
<th>Rate</th>
<th>Year</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUSTRIA</td>
<td>620.8</td>
<td>1989</td>
<td>847.0</td>
<td>2000</td>
<td>Ministry of Social Affairs, Public Health and the Environment</td>
</tr>
<tr>
<td>DENMARK</td>
<td>419.0</td>
<td>1987</td>
<td>434.8</td>
<td>2001</td>
<td>Hospital Discharge Register, Stakes. From 1998 Stakes Care Register</td>
</tr>
<tr>
<td>FINLAND</td>
<td>644.0</td>
<td>1987</td>
<td>660.6</td>
<td>2001</td>
<td>Hospital Discharge Register, Stakes. From 1998 Stakes Care Register</td>
</tr>
<tr>
<td>FRANCE</td>
<td>279.3</td>
<td>1993</td>
<td>214.3</td>
<td>2000</td>
<td>Federal Statistical Office, Hospital statistics - diagnostic data of the hospital patients</td>
</tr>
<tr>
<td>GREECE</td>
<td>365.0</td>
<td>1997</td>
<td>384.5</td>
<td>1998</td>
<td>Hospital in-Patient Enquiry; figures refer to discharges and not to individual people. Data from private, maternity or psychiatric hospitals are not included</td>
</tr>
<tr>
<td>IRELAND</td>
<td>223.5</td>
<td>1994</td>
<td>258.9</td>
<td>2001</td>
<td>ISTAT-Data on discharges are obtained by a sample survey referred to discharges over the first week in each month of the year. Under the hypothesis of uniform distribution of discharges in the whole month, an estimation of annual discharges is obtained multiplying the sample data by a coefficient (4.35 = average number of weeks in a month); January 2001, Ministry of Health: information derives from S.D.O. (Scheda di Dimissione Ospedaliera) and refers to all public and private hospitals</td>
</tr>
<tr>
<td>ITALY</td>
<td>369.3</td>
<td>1984</td>
<td>482.0</td>
<td>2000</td>
<td>Dutch Centre for Health Care Information: National Medical Registry</td>
</tr>
<tr>
<td>LUXEMBOURG</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>NETHERLANDS</td>
<td>175.3</td>
<td>1990</td>
<td>185.8</td>
<td>2001</td>
<td>-</td>
</tr>
<tr>
<td>NORWAY</td>
<td>292.1</td>
<td>1991</td>
<td>321.3</td>
<td>2001</td>
<td>Hospital Discharge Register, Stakes. From 1998 Stakes Care Register</td>
</tr>
<tr>
<td>PORTUGAL</td>
<td>290.4</td>
<td>1994</td>
<td>353.7</td>
<td>2001</td>
<td>Hospital Discharge Register, Stakes. From 1998 Stakes Care Register</td>
</tr>
<tr>
<td>SPAIN</td>
<td>104.8</td>
<td>1986</td>
<td>220.8</td>
<td>1997</td>
<td>December 2001: Total number of patients discharged from all hospitals during the given calendar year with the principal diagnosis falling into the group of Chapter VII of ICD-9MC. Source: National Statistics Institute. Hospital Morbidity Survey</td>
</tr>
<tr>
<td>SWEDEN</td>
<td>617.2</td>
<td>1987</td>
<td>494.4</td>
<td>2001</td>
<td>ICD-9: 390-459. Source: Hospital Discharge Register, NBHW</td>
</tr>
<tr>
<td>UNITED KINGDOM</td>
<td>231.1</td>
<td>1980</td>
<td>257.0</td>
<td>1994</td>
<td>January 2001: data refer to Great Britain only. Change of basis (definition) in 1998</td>
</tr>
<tr>
<td>EU average</td>
<td>342.8</td>
<td>1992</td>
<td>385.5</td>
<td>2001</td>
<td>EU average</td>
</tr>
</tbody>
</table>
**Table 2**: Table summarising EU population involved in the MONICA Project for Coronary events (7; WHO-MONICA coronary event registration data book 1980-1995)

<table>
<thead>
<tr>
<th>Country</th>
<th>Population</th>
<th>Years of Study</th>
<th>ICD Version Used (*)</th>
<th>Finding Methods (**)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belgium</td>
<td>Charleroi</td>
<td>1983 - 1992</td>
<td>9</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Ghent</td>
<td>1983 - 1992</td>
<td>9</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Luxembourg</td>
<td>1985 - 1991</td>
<td>9</td>
<td>M</td>
</tr>
<tr>
<td>Denmark</td>
<td>Glostrup</td>
<td>1982 - 1991</td>
<td>8</td>
<td>C</td>
</tr>
<tr>
<td>France</td>
<td>Lille</td>
<td>1985 - 1994</td>
<td>9</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td>Strasbourg</td>
<td>1985 - 1993</td>
<td>9</td>
<td>C</td>
</tr>
<tr>
<td></td>
<td>Toulouse</td>
<td>1985 - 1993</td>
<td>9</td>
<td>C</td>
</tr>
<tr>
<td>Germany</td>
<td>Augsburg</td>
<td>1985 - 1994</td>
<td>9</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Bremen</td>
<td>1985 - 1992</td>
<td>9</td>
<td>C</td>
</tr>
<tr>
<td></td>
<td>East Germany (***)</td>
<td>1984 - 1993</td>
<td>9</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td>Rhein-Neckar Region</td>
<td>1984 - 1988</td>
<td>9</td>
<td>H</td>
</tr>
<tr>
<td>Italy</td>
<td>Area Brianza</td>
<td>1985 - 1994</td>
<td>9</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Friuli</td>
<td>1984 - 1993</td>
<td>9</td>
<td>C</td>
</tr>
<tr>
<td>Spain</td>
<td>Catalonia</td>
<td>1985 - 1994</td>
<td>9</td>
<td>C</td>
</tr>
<tr>
<td>Sweden</td>
<td>Gothenburg</td>
<td>1984 - 1994</td>
<td>8</td>
<td>H</td>
</tr>
<tr>
<td>UK</td>
<td>Belfast</td>
<td>1983 - 1993</td>
<td>9</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td>Glasgow</td>
<td>1985 - 1994</td>
<td>9</td>
<td>C</td>
</tr>
</tbody>
</table>

(*) ICD version used indicates the version of the International Classification of Diseases. 8, 9 (1987) means that version 8 was used until 1986, and version 9 was used thereafter.

(**) “H” indicates hot pursuit, non-fatal events identified mainly at hospital admission; “C”, cold pursuit, non-fatal events identified from hospital discharge; and “M”, mixed pursuit, the combination of hot and cold pursuit.

(***) More fatal and non-fatal events are to be added.
Table 3: Table summarising EU population involved in the MONICA Project for Stroke  

<table>
<thead>
<tr>
<th>Country</th>
<th>Population</th>
<th>Years of Study</th>
<th>ICD Version Used (*)</th>
<th>Finding Methods (**)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germany</td>
<td>Halle County</td>
<td>1984 – 1988</td>
<td>9</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td>Karl-Marx Stadt</td>
<td>1985 - 1989</td>
<td>9</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td>Rest of DDR</td>
<td>1984 - 1989</td>
<td>9</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td>Rhein-Neckar</td>
<td>1984 - 1987</td>
<td>9</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td>Region</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>Friuli</td>
<td>1984 - 1993</td>
<td>9</td>
<td>C</td>
</tr>
</tbody>
</table>

(*) ICD version used indicates the version of the International Classification of Diseases. 8, 9 (1987) means that version 8 was used until 1986, and version 9 was used thereafter.

(**) “H” indicates hot pursuit, non-fatal events identified mainly at hospital admission; “C”, cold pursuit.
Non-fatal events identified from hospital discharge; and “M”, mixed pursuit, combination of hot and cold pursuit.
<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>Disease</th>
<th>Area</th>
<th>DRG</th>
<th>ICD</th>
<th>1st-last years</th>
<th>Age range</th>
<th>Population</th>
<th>Coverage</th>
<th>Mortal. linkage</th>
<th>Indicators</th>
<th>In hospital</th>
<th>Access data</th>
<th>Valid</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IHD</td>
<td>AMI</td>
<td>CVA</td>
<td>HF</td>
<td>Nat.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Men x1000</td>
<td>Women x1000</td>
<td>Total x1000</td>
<td>%</td>
<td>Hosp rate</td>
<td>N° pats admitt.</td>
<td>N° stays</td>
<td>Length of stays</td>
</tr>
<tr>
<td>Austria</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>IX 1997</td>
<td>all</td>
<td>3,941</td>
<td>4,170</td>
<td>8,111</td>
<td>100</td>
<td>-</td>
<td>✓</td>
</tr>
<tr>
<td>Belgium</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>IX 1995</td>
<td>all</td>
<td>5,018</td>
<td>5,245</td>
<td>10,263</td>
<td>100</td>
<td>-</td>
<td>✓</td>
</tr>
<tr>
<td>Denmark</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓ ✓</td>
<td>VII,X</td>
<td>all</td>
<td>2,654</td>
<td>2,714</td>
<td>5,368</td>
<td>100</td>
<td>ID</td>
<td>✓</td>
</tr>
<tr>
<td>Finland</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>X 1982</td>
<td>all</td>
<td>2,500</td>
<td>2,500</td>
<td>5,000</td>
<td>100</td>
<td>ID</td>
<td>✓</td>
</tr>
<tr>
<td>France</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓ ✓</td>
<td>X 1997</td>
<td>all</td>
<td>all</td>
<td>all</td>
<td>60,000</td>
<td>100</td>
<td>-</td>
<td>✓</td>
</tr>
<tr>
<td>Germany</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓ ✓</td>
<td>X 1993</td>
<td>all</td>
<td>all</td>
<td>all</td>
<td>80,000</td>
<td>99.9</td>
<td>-</td>
<td>✓</td>
</tr>
<tr>
<td>Italy</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓ ✓</td>
<td>IX 1998</td>
<td>all</td>
<td>28,000</td>
<td>29,000</td>
<td>57,000</td>
<td>95</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓ ✓</td>
<td>&gt;120 hosp</td>
<td>- IX</td>
<td>1978-2000</td>
<td>all</td>
<td>all</td>
<td>all</td>
<td>16,000</td>
<td>99</td>
</tr>
<tr>
<td>Norway</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓ ✓</td>
<td>X 1990-2000</td>
<td>all</td>
<td>all</td>
<td>all</td>
<td>4,400</td>
<td>100</td>
<td>-</td>
<td>✓</td>
</tr>
<tr>
<td>Portugal</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓ ✓</td>
<td>IX 1993-2000</td>
<td>all</td>
<td>all</td>
<td>all</td>
<td>4,570</td>
<td>4,919</td>
<td>9,490</td>
<td>90</td>
</tr>
<tr>
<td>Spain (**)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓ ✓</td>
<td>IX 1977-1998</td>
<td>all</td>
<td>all</td>
<td>all</td>
<td>39,413</td>
<td>100</td>
<td>-</td>
<td>✓</td>
</tr>
<tr>
<td>Sweden</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓ ✓</td>
<td>X 1987</td>
<td>all</td>
<td>4390</td>
<td>4490</td>
<td>8880</td>
<td>100</td>
<td>ID</td>
<td>✓</td>
</tr>
<tr>
<td>UK - England</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓ ✓</td>
<td>X 1989-2002</td>
<td>all</td>
<td>all</td>
<td>all</td>
<td>90-95</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>UK - Scotland</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓ ✓</td>
<td>X 1962-2002</td>
<td>all</td>
<td>all</td>
<td>all</td>
<td>100</td>
<td>DOB, sex zipcode</td>
<td>-</td>
<td>✓</td>
</tr>
</tbody>
</table>

(*) National Centre of Welfare and Health
(**) Statistical data are available only for 50% of the total HDR; (#) National Board of Health and Welfare

69
<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>Disease</th>
<th>Sampling</th>
<th>Indicators</th>
<th>Periodicity</th>
<th>Source</th>
<th>1st year</th>
<th>Age range</th>
<th>Population</th>
<th>Response</th>
<th>Access data</th>
<th>Stand meth.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ischaemic heart disease, acute myocardial infarction, cerebrovascular accidents, heart failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surveys at national level</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IHD</td>
<td>AMI</td>
<td>CVA</td>
<td>HF</td>
<td>x 1000</td>
<td>Preval</td>
<td>Other</td>
<td>Quest</td>
<td>Exam</td>
<td>Men x1000</td>
</tr>
<tr>
<td>Austria</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>x 1000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Belgium HIS</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>4-years</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>5.9</td>
</tr>
<tr>
<td>Denmark HIS</td>
<td>General questions on health</td>
<td>5-20</td>
<td>✓</td>
<td>4-years</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>1987</td>
<td>16  →</td>
<td>8.2</td>
<td>8.5</td>
</tr>
<tr>
<td>Finland HEALTH 2000</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>15-years</td>
<td>✓</td>
<td>✓</td>
<td>2000</td>
<td>25  →</td>
<td>2500</td>
</tr>
<tr>
<td>France</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>10-years</td>
<td>✓</td>
<td>✓</td>
<td>1960</td>
<td>0  →</td>
<td>-</td>
</tr>
<tr>
<td>Germany- National HIS/HES</td>
<td></td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>4/8-years</td>
<td>✓</td>
<td>✓</td>
<td>1998</td>
<td>18-79</td>
<td>3.4</td>
</tr>
<tr>
<td>Greece CARDIO 2000</td>
<td></td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>✓</td>
<td>✓</td>
<td>2000</td>
<td>26-84</td>
<td>0.7</td>
</tr>
<tr>
<td>Italy HIS</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>70</td>
<td>3-4 years</td>
<td>✓</td>
<td>-</td>
<td>1980</td>
<td>0  →</td>
<td>-</td>
</tr>
<tr>
<td>Netherlands POLS</td>
<td>Question about circulatory system</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>yearly</td>
<td>✓</td>
<td>✓</td>
<td>1981</td>
<td>0  →</td>
<td>5.4</td>
</tr>
<tr>
<td>Norway HIS</td>
<td>#CAPI</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>3-years</td>
<td>✓</td>
<td>-</td>
<td>1998</td>
<td>16  →</td>
<td>-</td>
</tr>
<tr>
<td>Portugal HIS</td>
<td>Question about circulatory system</td>
<td>49.718</td>
<td>-</td>
<td>% by cause</td>
<td>1987</td>
<td>1995, 1998</td>
<td>✓</td>
<td>-</td>
<td>1987</td>
<td>1-79</td>
<td>20</td>
</tr>
<tr>
<td>Portugal EPICA</td>
<td>-</td>
<td>6.3</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>1998</td>
<td>25-80+</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Spain - Encuesta nacional de salud</td>
<td>Only one question on disease in general</td>
<td>8.4</td>
<td>-</td>
<td>Irregular, lately every two years</td>
<td>✓</td>
<td>-</td>
<td>1987</td>
<td>0  →</td>
<td>4</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>Sweden National survey on living conditions</td>
<td>General questions on health</td>
<td>12-13</td>
<td>every 2 yrs</td>
<td>✓</td>
<td>-</td>
<td>1975</td>
<td>16-84</td>
<td>7.5</td>
<td>Statistic Sweden</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>UK Health Survey for England</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>23</td>
<td>✓</td>
<td>1993</td>
<td>16  →</td>
<td>7</td>
<td>9</td>
<td>16</td>
</tr>
<tr>
<td>UK – Scottish Health Survey</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>12</td>
<td>✓</td>
<td>1995</td>
<td>16-74</td>
<td>-</td>
<td>9</td>
<td>76</td>
</tr>
</tbody>
</table>
### TABLE 5 b

**SOURCE:**  SURVEYS AT REGIONAL LEVEL

**DISEASE:**  ISCHAEMIC HEART DISEASE, ACUTE MYOCARDIAL INFARCTION,  CEREBROVASCULAR ACCIDENTS, HEART FAILURE

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>Disease</th>
<th>Sample</th>
<th>Indicators</th>
<th>Periodicity</th>
<th>Source</th>
<th>1st year</th>
<th>Age range</th>
<th>Population</th>
<th>Resp. rate</th>
<th>Access data</th>
<th>Standard method.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IHD</td>
<td>AMI</td>
<td>CVA</td>
<td>HF</td>
<td>x 1000</td>
<td>Preval</td>
<td>Other</td>
<td>Quest</td>
<td>Exam</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Belgium</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1992 last</td>
<td>✓</td>
<td>-</td>
<td>1983 25-64</td>
</tr>
<tr>
<td>Ghent</td>
<td>Charleroi</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td>✓</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>6</td>
<td>✓</td>
<td>-</td>
<td>5-years</td>
<td>✓</td>
<td>-</td>
<td>1972 25-74</td>
</tr>
<tr>
<td>FINRISK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>185 189 374</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>6.5</td>
<td>✓</td>
<td>-</td>
<td>5-years</td>
<td>✓</td>
<td>-</td>
<td>1984 25-74</td>
</tr>
<tr>
<td>Augsburg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 2 4 66</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>-</td>
<td>7</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>1997 20-80</td>
</tr>
<tr>
<td>SHIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 2 4 69</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>6</td>
<td>✓</td>
<td>-</td>
<td>no</td>
<td>✓</td>
<td>✓</td>
<td>1998 35-74</td>
</tr>
<tr>
<td>OEC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.2 3.2 6.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Netherlands</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>10.3</td>
<td>✓</td>
<td>Incid.</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>1990 55→</td>
</tr>
<tr>
<td>Rotterdam ERGO</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.1 4.9 8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>78 Erasmus Univ.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>WHO</td>
</tr>
<tr>
<td>Netherlands</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>10 x</td>
<td>✓</td>
<td>yearly</td>
<td>(1993-97)</td>
<td>✓</td>
<td>-</td>
<td>1993 20-59</td>
</tr>
<tr>
<td>Morgen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>year</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10 12 22</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>55 RIVM protocol</td>
</tr>
<tr>
<td>Norway</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>65</td>
<td>✓</td>
<td>5 to 10 yrs</td>
<td>-</td>
<td>✓</td>
<td>-</td>
<td>1984 20-90</td>
</tr>
<tr>
<td>(**)</td>
<td>Nord-Trondelag</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 35 65</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>69 HUNT Questionn</td>
</tr>
<tr>
<td>Norway</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>37</td>
<td>✓</td>
<td>5 to 10 yrs</td>
<td>-</td>
<td>✓</td>
<td>-</td>
<td>1992 39-72</td>
</tr>
<tr>
<td>Hordaland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- 26 26</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bergen Univ. Questionn</td>
</tr>
<tr>
<td>Spain-MONICA</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>5</td>
<td>✓</td>
<td>last 1996</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>1986 25-64</td>
</tr>
<tr>
<td>Catalonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.8 1.6 3.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>72 MONICA</td>
</tr>
<tr>
<td>Sweden</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>-</td>
<td>1.5</td>
<td>✓</td>
<td>5-years</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>1985 25-64</td>
</tr>
<tr>
<td>Gothenburg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- - 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>70-73 Ostra Hospital</td>
</tr>
<tr>
<td>Sweden</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>-</td>
<td>2/2.5</td>
<td>✓</td>
<td>4/5-years</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>1986 25-74</td>
</tr>
<tr>
<td>Northern</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- 1.95</td>
</tr>
<tr>
<td>Sweden</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>73-83 Umea Univ.</td>
</tr>
</tbody>
</table>

(A), (B), (C), (D) distinguish different Surveys in the same country

(**) surveys like those in Nord-Trondelag are conducted in several regions, with 5-10 year's intervals (e.g. FINNMARK)

# Computer Assisted Personal Interview (CAPI)

## National Institute of Public Health, Denmark
<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>Disease</th>
<th>Area</th>
<th>Source</th>
<th>1st year</th>
<th>Age range</th>
<th>Population</th>
<th>Resp. rate</th>
<th>Indicators</th>
<th>Access data</th>
<th>Valid</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IHD</td>
<td>AMI</td>
<td>CVA</td>
<td>H F</td>
<td>Nat Reg</td>
<td>Sample x1000</td>
<td>Quest Exam</td>
<td>Re-exam</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>School of Pub. Health</td>
</tr>
<tr>
<td>Denmark (A)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>14</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>CCHS, Bispebjerg Hospital</td>
</tr>
<tr>
<td>Denmark (B)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>25</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Res. Centre for Prevention and Health</td>
</tr>
<tr>
<td>Denmark DANCOS F-U of Nat. Health Interview Survey</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>46</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>Nat. Inst. of Public Health</td>
</tr>
<tr>
<td>Finland FINRISK</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>36</td>
<td>-</td>
<td>-</td>
<td>✓</td>
<td>KTL MON</td>
</tr>
<tr>
<td>Finland HEALTH 2000</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>✓</td>
<td>KTL MON, WHO</td>
</tr>
<tr>
<td>France - PRIME</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>7.8</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>INSERM MON</td>
</tr>
<tr>
<td>Germany KORA</td>
<td>-</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>✓</td>
<td>18</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>GSF MON</td>
</tr>
<tr>
<td>Germany (B) (*)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>6.5</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Essen Univ. MON</td>
</tr>
<tr>
<td>Italy</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>47</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Milano Univ. MON</td>
</tr>
<tr>
<td>Netherlands Rotterdam ERGO</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>10.3</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Erasmus Univ. WHO</td>
</tr>
<tr>
<td>Netherlands Zutphen</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>1.3</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>RIVM SCS</td>
</tr>
<tr>
<td>Netherlands Doetinchem</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>6</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>RIVM protocol</td>
</tr>
<tr>
<td>Norway</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Portugal</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Spain</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sweden</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>4.178</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Karolinska Institutet protocol</td>
</tr>
<tr>
<td>Stockholm</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>7.7</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>UCL WHO</td>
</tr>
<tr>
<td>United Kingdom BRHS</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>7.7</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

(A), (B), (C) distinguish different Longitudinal Studies in the same country
(*) Germany (B) is ongoing (RECALL Study); # National Institute of Public Health, Denmark
<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>Disease</th>
<th>Area</th>
<th>GPs proportion</th>
<th>1st year</th>
<th>Duration</th>
<th>Age range</th>
<th>Population</th>
<th>Indicators</th>
<th>Access data</th>
<th>Valid</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IHD</td>
<td>AMI</td>
<td>CVA</td>
<td>HF</td>
<td>Nat.</td>
<td>Reg.</td>
<td>Sample</td>
<td>Other</td>
<td>%</td>
<td>years</td>
</tr>
<tr>
<td>Austria</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Belgium</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Denmark</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Finland</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>France</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Germany</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Italy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Netherlands</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>228</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Netherlands</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>56</td>
<td>-</td>
<td>20</td>
</tr>
<tr>
<td>Norway</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Portugal</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>200</td>
<td>-</td>
<td>0.5</td>
</tr>
<tr>
<td>Spain</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sweden</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>UK – England</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>137</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>UK - Scotland</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>80</td>
<td>-</td>
<td>-</td>
<td>8</td>
</tr>
</tbody>
</table>

(A), (B) distinguish different General Practitioners Registers in the same country
<table>
<thead>
<tr>
<th>Country</th>
<th>Area</th>
<th>Year</th>
<th>Age range</th>
<th>Population</th>
<th>Sources</th>
<th>Indicators</th>
<th>Access data</th>
<th>Valid</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Men x1000</td>
<td>Women x1000</td>
<td>Total x1000</td>
<td>Mortal</td>
<td>HDR</td>
</tr>
<tr>
<td>Austria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>Ghent</td>
<td>1983-1997</td>
<td>25-69</td>
<td>50</td>
<td>51</td>
<td>101</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Ghent</td>
<td>1998</td>
<td>25-74</td>
<td>70</td>
<td>72</td>
<td>142</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Bruges</td>
<td>1999</td>
<td>25-74</td>
<td>75</td>
<td>76</td>
<td>151</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Charleroi</td>
<td>1983</td>
<td>25-69</td>
<td>58</td>
<td>59</td>
<td>117</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Denmark</td>
<td></td>
<td>1977-1983</td>
<td>0-74</td>
<td>493</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
</tr>
<tr>
<td>Finland</td>
<td>FINAMI</td>
<td>1993-2002</td>
<td>35-100</td>
<td>104</td>
<td>128</td>
<td>232</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>France</td>
<td></td>
<td>1985</td>
<td>35-74</td>
<td>✓</td>
<td>✓</td>
<td>1,800</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td>1985</td>
<td>25-74</td>
<td>200</td>
<td>200</td>
<td>400</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Italy</td>
<td>8 areas</td>
<td>1996-1999</td>
<td>35-74</td>
<td>-</td>
<td>-</td>
<td>3,360</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Netherlands</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norway Regional MI</td>
<td></td>
<td>2001</td>
<td>18</td>
<td>150</td>
<td>150</td>
<td>300</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Norway (Finmark)</td>
<td></td>
<td>2000</td>
<td>15</td>
<td>29</td>
<td>29</td>
<td>58</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Portugal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>Barcelon</td>
<td>1985-1998</td>
<td>25-74</td>
<td>380</td>
<td>386</td>
<td>766</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Sweden Northern Swed.</td>
<td></td>
<td>1985-1998</td>
<td>25-74</td>
<td>250</td>
<td>260</td>
<td>510</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>UK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COUNTRY</td>
<td>Area</td>
<td>Year</td>
<td>Age range</td>
<td>Population</td>
<td>Sources</td>
<td>Indicators</td>
<td>Access data</td>
<td>Valid</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------</td>
<td>------</td>
<td>-----------</td>
<td>------------</td>
<td>---------</td>
<td>------------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td><strong>National Registers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Denmark</td>
<td>-</td>
<td>1978</td>
<td>0</td>
<td>5,368</td>
<td>✓✓</td>
<td>-</td>
<td>In/out hospital</td>
<td>NIPH #</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MONICA Register</td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>-</td>
<td>1991</td>
<td>0</td>
<td>5,000</td>
<td></td>
<td></td>
<td>KTL, Stakes</td>
<td></td>
</tr>
<tr>
<td>Norway-cardiac surgery register</td>
<td>-</td>
<td>1995</td>
<td>20</td>
<td>4.5 (2000)</td>
<td></td>
<td>Information by heart surgeon</td>
<td>In hospital</td>
<td>Norwegian surgeons’ association</td>
</tr>
<tr>
<td>Sweden</td>
<td>-</td>
<td>1987</td>
<td>0</td>
<td>8,880</td>
<td>✓✓</td>
<td>-</td>
<td>In/out hospital</td>
<td>Nat. Board of Health &amp; Welf</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Recommended national diagnostic criteria</td>
<td></td>
</tr>
</tbody>
</table>

# National Institute of Public Health, Denmark
### TABLE 9  

**DISEASE:** CEREBROVASCULAR ACCIDENTS  
**SOURCE:** POPULATION BASED REGISTER

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>Area</th>
<th>Year</th>
<th>Age range</th>
<th>Population</th>
<th>Sources</th>
<th>Indicators</th>
<th>Access data</th>
<th>Valid</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Men x1000</td>
<td>Women x1000</td>
<td>Total x1000</td>
<td>Mort. HDR</td>
<td>Other Incid.</td>
<td>Preval</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Regional Registers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Belgium</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Denmark</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Finland FINSTROKE</td>
<td>-</td>
<td>1993-1997</td>
<td>25-99</td>
<td>97</td>
<td>114</td>
<td>232</td>
<td>✓ ✔ -</td>
<td>✓ - ✓</td>
</tr>
<tr>
<td>France - Dijon Stroke Register</td>
<td>Dijon</td>
<td>1985 Æ01 Æ 01</td>
<td>70</td>
<td>80</td>
<td>150</td>
<td>✓ ✔ GP</td>
<td>-</td>
<td>✓ -</td>
</tr>
<tr>
<td>Germany</td>
<td>-</td>
<td>1994 Æ18 Æ 18</td>
<td>48</td>
<td>52</td>
<td>100</td>
<td>✓ ✔ case ascertai</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Italy</td>
<td>8 areas</td>
<td>1996-1999</td>
<td>35-74</td>
<td>-</td>
<td>-</td>
<td>3,360</td>
<td>✓ ✔ -</td>
<td>✓ ✓ ✓</td>
</tr>
<tr>
<td>Netherlands</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Norway</td>
<td>-</td>
<td>1998 Æ24-95+ Æ</td>
<td>29</td>
<td>29</td>
<td>58</td>
<td>✓ ✔ hosp. journal</td>
<td>✓ ✓</td>
<td>✓ ✓</td>
</tr>
<tr>
<td>Portugal</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Spain</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Northern Sweden</td>
<td>-</td>
<td>1985 Æ25-75 Æ</td>
<td>160</td>
<td>162</td>
<td>322</td>
<td>✓ ✔ -</td>
<td>✓ - ✓</td>
<td>In/out hospital</td>
</tr>
<tr>
<td>UK</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>National Registers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Denmark</td>
<td>-</td>
<td>1978 Æ0 Æ</td>
<td>2,654</td>
<td>2,714</td>
<td>5,368</td>
<td>✓ ✔ -</td>
<td>✓ -</td>
<td>-</td>
</tr>
<tr>
<td>Finland</td>
<td>1991 Æ25-99 Æ</td>
<td>5,000</td>
<td>✓ ✔</td>
<td>✓</td>
<td>In/out hospital</td>
<td>KTL. stakes comparison with FINSTROKE register</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweden Riks-Stroke</td>
<td>-</td>
<td>1995 Æ01 Æ</td>
<td>4,390</td>
<td>4,490</td>
<td>8,880</td>
<td>✓ ✔ -</td>
<td>✓ -</td>
<td>✓</td>
</tr>
</tbody>
</table>

(*) HDR = Hospital Discharge Records
### Table 10
Registers of AMI: case definition in each country

<table>
<thead>
<tr>
<th>Country</th>
<th>ICD version</th>
<th>Mortality ICD codes *</th>
<th>HDR ICD codes *</th>
<th>Linkage mortality / HDR</th>
<th>Validation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belgium Charleroi, Ghent, Bruges</td>
<td>IX</td>
<td>410-414</td>
<td>410-414, PTCA, CAGB</td>
<td>name, date of birth</td>
<td>MONICA, troponine</td>
</tr>
<tr>
<td>Northern Denmark</td>
<td>VIII, X</td>
<td>410</td>
<td>410</td>
<td>ID</td>
<td>----</td>
</tr>
<tr>
<td>Finland</td>
<td>X</td>
<td>410-414, 798</td>
<td>410, 411, 413</td>
<td>ID</td>
<td>MONICA, troponine</td>
</tr>
<tr>
<td>France</td>
<td>X</td>
<td>410-414</td>
<td>410-414, 428</td>
<td>name, date of birth</td>
<td>MONICA</td>
</tr>
<tr>
<td>Germany</td>
<td>X</td>
<td>410-414, 428, 798</td>
<td>410-414, 428, PTCA, CAGB</td>
<td>name, date of birth</td>
<td>MONICA</td>
</tr>
<tr>
<td>Italy-MONICA, Italy</td>
<td>IX</td>
<td>410-414, 798, other</td>
<td>410-414</td>
<td>name, date of birth</td>
<td>MONICA</td>
</tr>
<tr>
<td>Norway</td>
<td>X</td>
<td>410-414, 428, 798</td>
<td>410-414, 428 PTCA</td>
<td>ID</td>
<td>MONICA, troponine</td>
</tr>
<tr>
<td>Spain</td>
<td>IX</td>
<td>410-414, 428, 798, other</td>
<td>410-414</td>
<td>name, date of birth</td>
<td>MONICA</td>
</tr>
<tr>
<td>Northern Sweden MONICA</td>
<td>IX, X</td>
<td>410</td>
<td>410</td>
<td>ID</td>
<td>MONICA</td>
</tr>
<tr>
<td>Denmark</td>
<td>VIII, X</td>
<td>410-414</td>
<td>410</td>
<td>ID</td>
<td>Recommended national diagnostic criteria and MONICA</td>
</tr>
<tr>
<td>Finland</td>
<td>X</td>
<td>410-414, 798</td>
<td>410, 411, 413</td>
<td>ID</td>
<td>Clinical diagnosis, troponine</td>
</tr>
<tr>
<td>Sweden</td>
<td>IX, X</td>
<td>410</td>
<td>410</td>
<td>ID</td>
<td>Recommended national diagnostic criteria</td>
</tr>
</tbody>
</table>

* All codes are presented in the ICD-9 revision to facilitate the comparison.
<table>
<thead>
<tr>
<th>Country</th>
<th>ICD version</th>
<th>Mortality ICD codes</th>
<th>HDR ICD codes</th>
<th>Linkage mortality / HDR</th>
<th>Validation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finland</td>
<td>X</td>
<td>430-438</td>
<td>430-438</td>
<td>ID</td>
<td>MONICA</td>
</tr>
<tr>
<td>France</td>
<td>X</td>
<td>430-438</td>
<td>430-438</td>
<td>ID, date of birth</td>
<td>CT-Scan</td>
</tr>
<tr>
<td>Germany</td>
<td>X</td>
<td>430-438</td>
<td>430-438</td>
<td>name, date of birth</td>
<td>CT-Scan, Health Insurance</td>
</tr>
<tr>
<td>Italy</td>
<td>IX</td>
<td>430-434, 436-438</td>
<td>430-434, 436-438</td>
<td>name, date of birth</td>
<td>MONICA</td>
</tr>
<tr>
<td>Norway</td>
<td>X</td>
<td>430-438</td>
<td>431, 434, 436</td>
<td>ID</td>
<td>MONICA</td>
</tr>
<tr>
<td>Sweden MONICA</td>
<td>IX, X</td>
<td>430-434, 436</td>
<td>430-438</td>
<td>ID</td>
<td>MONICA</td>
</tr>
</tbody>
</table>

**Regional Registers**

<table>
<thead>
<tr>
<th>Country</th>
<th>ICD version</th>
<th>Mortality ICD codes</th>
<th>HDR ICD codes</th>
<th>Linkage mortality / HDR</th>
<th>Validation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denmark</td>
<td>VIII, X</td>
<td>430-438</td>
<td>430-438</td>
<td>ID</td>
<td>-</td>
</tr>
<tr>
<td>Finland</td>
<td>X</td>
<td>430-438</td>
<td>430-438</td>
<td>ID</td>
<td>Clinical diagnosis, CT / MRI</td>
</tr>
<tr>
<td>Sweden Riks-Stroke</td>
<td>X</td>
<td>431, 434, 436</td>
<td>431, 434, 436</td>
<td>ID</td>
<td>Clinical diagnosis</td>
</tr>
</tbody>
</table>

(* all codes are presented in the ICD-9 revision to facilitate the comparison)
<table>
<thead>
<tr>
<th>ICD-VIII</th>
<th>ICD-VIII label</th>
<th>ICD-IX</th>
<th>ICD-IX label</th>
<th>ICD-X</th>
<th>ICD-X label</th>
</tr>
</thead>
<tbody>
<tr>
<td>393-398</td>
<td>Chronic rheumatic heart disease</td>
<td>105-109</td>
<td>Rheumatic heart disease</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Rheumatic heart disease

<table>
<thead>
<tr>
<th>410 - 414</th>
<th>Ischaemic heart disease</th>
<th>410 - 414</th>
<th>Ischaemic heart disease</th>
<th>120 - 125</th>
<th>Ischaemic heart disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>410</td>
<td>Acute myocardial infarction</td>
<td>410</td>
<td>Acute myocardial infarction</td>
<td>121, 122</td>
<td>Acute myocardial infarction</td>
</tr>
<tr>
<td>411</td>
<td>Other acute and subacute forms of ischaemic heart disease</td>
<td>411</td>
<td>Other acute and subacute forms of ischaemic heart disease</td>
<td>120.0</td>
<td>Other acute ischaemic heart disease</td>
</tr>
<tr>
<td>412</td>
<td>Old myocardial infarction</td>
<td>412</td>
<td>Old myocardial infarction</td>
<td>125.2</td>
<td>Old myocardial infarction</td>
</tr>
<tr>
<td>413</td>
<td>Angina pectoris</td>
<td>413</td>
<td>Angina pectoris</td>
<td>120</td>
<td>Angina pectoris</td>
</tr>
<tr>
<td>414</td>
<td>Other forms of chronic ischaemic heart disease</td>
<td>414</td>
<td>Other forms of chronic ischaemic heart disease</td>
<td>125 (excluding 125.2)</td>
<td>Chronic ischaemic heart disease</td>
</tr>
</tbody>
</table>

### Ischaemic heart disease

<table>
<thead>
<tr>
<th>428</th>
<th>Heart failure</th>
<th>428</th>
<th>Heart failure</th>
<th>150</th>
<th>Heart failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>427.0</td>
<td>Congestive heart failure</td>
<td>427.0</td>
<td>Congestive heart failure</td>
<td>150.0</td>
<td>Congestive heart failure</td>
</tr>
<tr>
<td>428.1</td>
<td>Left heart failure, acute oedema of lung</td>
<td>428.1</td>
<td>Left heart failure, acute oedema of lung</td>
<td>150.1</td>
<td>Left heart failure, acute oedema of lung</td>
</tr>
</tbody>
</table>

### Heart failure

<table>
<thead>
<tr>
<th>400-404</th>
<th>Hypertensive disease</th>
<th>401-405</th>
<th>Hypertensive disease</th>
<th>111-113</th>
<th>Hypertensive disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>415</td>
<td>Acute pulmonary heart disease</td>
<td>415</td>
<td>Acute pulmonary heart disease</td>
<td>126</td>
<td>Acute pulmonary heart disease</td>
</tr>
<tr>
<td>420-429</td>
<td>Other forms of heart disease</td>
<td>420-429</td>
<td>Other forms of heart disease</td>
<td>130-149, 151</td>
<td>Other forms of heart disease</td>
</tr>
<tr>
<td>426-427</td>
<td>Conduction disorders and cardiac dysrhythmias</td>
<td>426-427</td>
<td>Conduction disorders and cardiac dysrhythmias</td>
<td>144-149</td>
<td>Conduction disorders and cardiac dysrhythmias</td>
</tr>
<tr>
<td>440</td>
<td>Atherosclerosis</td>
<td>440</td>
<td>Atherosclerosis</td>
<td>170</td>
<td>Atherosclerosis</td>
</tr>
<tr>
<td>441-442</td>
<td>Aortic aneurysm</td>
<td>441-442</td>
<td>Aortic aneurysm</td>
<td>171-172</td>
<td>Aortic aneurysm</td>
</tr>
<tr>
<td>444</td>
<td>Arterial embolism and thrombosis</td>
<td>444</td>
<td>Arterial embolism and thrombosis</td>
<td>174</td>
<td>Arterial embolism and thrombosis</td>
</tr>
<tr>
<td>451-456</td>
<td>Venous thromboembolic disease</td>
<td>451-456</td>
<td>Venous thromboembolic disease</td>
<td>180-187</td>
<td>Venous thromboembolic disease</td>
</tr>
</tbody>
</table>
Table 12: Conversion table between ICD-VIII, IX and X revisions

<table>
<thead>
<tr>
<th>ICD-VIII</th>
<th>ICD-VIII label</th>
<th>ICD-IX</th>
<th>ICD-IX label</th>
<th>ICD-X</th>
<th>ICD-X label</th>
</tr>
</thead>
<tbody>
<tr>
<td>430 - 438</td>
<td>Cerebrovascular diseases</td>
<td>430-438</td>
<td>Cerebrovascular diseases</td>
<td>I60 - I69, G45</td>
<td>Cerebrovascular diseases</td>
</tr>
<tr>
<td>430</td>
<td>Subarachnoid haemorrhage</td>
<td>430</td>
<td>Subarachnoid haemorrhage</td>
<td>I60</td>
<td>Subarachnoid haemorrhage</td>
</tr>
<tr>
<td>431</td>
<td>Cerebral haemorrhage</td>
<td>431</td>
<td>Intracerebral haemorrhage</td>
<td>I61</td>
<td>Intracerebral haemorrhage</td>
</tr>
<tr>
<td>432</td>
<td>Cerebral haemorrhage</td>
<td>432</td>
<td>Other and unspecified intracranial haemorrhage</td>
<td>I62</td>
<td>Other non-traumatic intracranial haemorrhage</td>
</tr>
<tr>
<td>432</td>
<td>Occlusion of precerebral arteries</td>
<td>433</td>
<td>Occlusion and stenosis of precerebral arteries</td>
<td>I65</td>
<td>Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction</td>
</tr>
<tr>
<td>433, 434</td>
<td>Cerebral thrombosis, cerebral embolism</td>
<td>434</td>
<td>Occlusion and stenosis of cerebral arteries</td>
<td>I66</td>
<td>Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction</td>
</tr>
<tr>
<td>433</td>
<td>Cerebral thrombosis</td>
<td>434, 435</td>
<td>Cerebral infarction</td>
<td>I63</td>
<td>Cerebral infarction</td>
</tr>
<tr>
<td>435</td>
<td>Transient cerebral ischaemia</td>
<td>435</td>
<td>Transient cerebral ischaemia</td>
<td>G45</td>
<td>Transient cerebral ischaemic attacks and related syndromes</td>
</tr>
<tr>
<td>436</td>
<td>Acute but ill-defined cerebrovascular disease</td>
<td>436</td>
<td>Acute, but ill-defined, cerebrovascular disease</td>
<td>I64</td>
<td>Stroke, not specified as haemorrhage or infarction</td>
</tr>
<tr>
<td>437, 438</td>
<td>Generalised ischaemic cerebrovascular disease, other and ill-defined cerebrovascular disease</td>
<td>437</td>
<td>Other and ill-defined cerebrovascular disease</td>
<td>I67, I68</td>
<td>Other cerebrovascular disease, Cerebrovascular disorders in diseases classified elsewhere</td>
</tr>
<tr>
<td>438</td>
<td>Late effects of cerebrovascular disease</td>
<td>438</td>
<td>Late effects of cerebrovascular disease</td>
<td>I69</td>
<td>Sequelae of cerebrovascular diseases</td>
</tr>
</tbody>
</table>

Sudden death

<table>
<thead>
<tr>
<th>ICD 9 CM</th>
<th>NOMESCO</th>
</tr>
</thead>
<tbody>
<tr>
<td>36.1</td>
<td>CABG</td>
</tr>
<tr>
<td>36.01-</td>
<td>FNA-FNE</td>
</tr>
<tr>
<td>36.06</td>
<td>FNG0</td>
</tr>
<tr>
<td>88.55-</td>
<td>Coronary angiography</td>
</tr>
<tr>
<td>88.57</td>
<td>XAC85 (Denmark)</td>
</tr>
<tr>
<td>35.0-</td>
<td>Valvular operations</td>
</tr>
<tr>
<td>.35.3,</td>
<td>FG, FJ, FK, FM</td>
</tr>
<tr>
<td>35.95,</td>
<td></td>
</tr>
<tr>
<td>35.96,</td>
<td></td>
</tr>
<tr>
<td>35.99</td>
<td></td>
</tr>
</tbody>
</table>
**Table 13**

**INDICATORS FOR ACUTE MYOCARDIAL INFARCTION**

(ICD-9 410, ICD-10 I21-I22)

<table>
<thead>
<tr>
<th>AMI</th>
<th>AVAILABLE</th>
<th>SHORT-TERM IMPLEMENTATION</th>
<th>LONG-TERM IMPLEMENTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEALTH STATUS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MORTALITY</strong></td>
<td><em>ICD-9 410-414 rate</em></td>
<td><em>ICD-9 410 rate</em></td>
<td>Validated mortality rate</td>
</tr>
<tr>
<td></td>
<td><em>ICD-10 120-125 rate</em></td>
<td><em>ICD-10 121-122 rate</em></td>
<td></td>
</tr>
<tr>
<td><strong>MORBIDITY</strong></td>
<td>Hospital Discharge Rate</td>
<td>Attack rate/incidence</td>
<td>Validated attack/incidence rate</td>
</tr>
<tr>
<td></td>
<td><em>ICD-9 410</em></td>
<td>1-day, 28-day case-fatality</td>
<td>Re-admission after 1 year</td>
</tr>
<tr>
<td></td>
<td><em>ICD-10 121, 122</em></td>
<td></td>
<td>1 year survival</td>
</tr>
<tr>
<td></td>
<td>In-hospital case-fatality</td>
<td></td>
<td>28-day case-fatality among first day survivors</td>
</tr>
<tr>
<td>HEALTH SYSTEM: HEALTH CARE UTILISATION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Medicine use</strong></td>
<td></td>
<td>Thrombolytic therapy</td>
<td></td>
</tr>
<tr>
<td><strong>Surgical operations and invasive procedures</strong></td>
<td></td>
<td></td>
<td>CABG per AMI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PTCA per AMI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Emergency CABG (within 24 hrs)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Emergency PTCA (within 24 hrs)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>30-day case-fatality rate for CABG</td>
</tr>
<tr>
<td><strong>In-patient care utilisation</strong></td>
<td>Aggregate bed-day rate</td>
<td>Median length of stay</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mean length of stay</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 14

INDICATORS FOR ACUTE CORONARY SYNDROMES

(ICD-9 410, 411, 413 ICD-10 I20, I21, I22, I24)

<table>
<thead>
<tr>
<th>ACS</th>
<th>SHORT-TERM IMPLEMENTATION</th>
<th>LONG-TERM IMPLEMENTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEALTH STATUS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MORTALITY</td>
<td><em>ICD-9</em> 410, 411 rate</td>
<td>Validated mortality rate</td>
</tr>
<tr>
<td></td>
<td><em>ICD-10</em> I20.0, I21, I22 rate</td>
<td></td>
</tr>
<tr>
<td>MORBIDITY</td>
<td>HDR <em>ICD-9</em> 410, 411</td>
<td>Validated attack rate/incidence</td>
</tr>
<tr>
<td></td>
<td><em>ICD-10</em> I20.0, I21, I22 rate</td>
<td></td>
</tr>
<tr>
<td>HEALTH SYSTEM:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEALTH CARE UTILISATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Surgical operations and</em></td>
<td></td>
<td>CABG per ACS</td>
</tr>
<tr>
<td><em>invasive procedures</em></td>
<td></td>
<td>PTCA per ACS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Emergency CABG (within 24 hrs) rate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Emergency PTCA (within 24 hrs) rate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ACS patients in ICU</td>
</tr>
<tr>
<td><em>In-patient care utilisation</em></td>
<td>Aggregate bed-day rate</td>
<td>Median length of stay</td>
</tr>
<tr>
<td></td>
<td>Mean length of stay</td>
<td></td>
</tr>
<tr>
<td>HEALTH STATUS</td>
<td>AVAILABLE</td>
<td>SHORT-TERM IMPLEMENTATION</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>MORTALITY</td>
<td>ICD-9 410-414, ICD-10 I20-I25</td>
<td>ICD-9 410-414+ 798 rate</td>
</tr>
<tr>
<td>DISABILITY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEALTH SYSTEM: HEALTH CARE UTILISATION</td>
<td>Surgical operations and invasive procedures</td>
<td>CABG rate, PTCA rate, Coronary angiography rate</td>
</tr>
</tbody>
</table>
Table 16

HEALTH STATUS INDICATOR FOR HEART FAILURE

(ICD-9 428, ICD-10 I50)

<table>
<thead>
<tr>
<th>HEART FAILURE</th>
<th>AVAILABLE</th>
<th>SHORT-TERM IMPLEMENTATION</th>
<th>LONG-TERM IMPLEMENTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEALTH STATUS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MORTALITY</td>
<td></td>
<td>ICD-9 428 rate</td>
<td>Validated mortality rate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ICD-10 150 rate</td>
<td></td>
</tr>
<tr>
<td>MORBIDITY</td>
<td></td>
<td>HDR ICD-9 428 rate</td>
<td>Validated hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>discharge rate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ICD-10 150 rate</td>
<td>Attack rate / Incidence</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Prevalence</td>
</tr>
<tr>
<td>DISABILITY</td>
<td></td>
<td></td>
<td>Functional disability and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>quality of life indicators</td>
</tr>
<tr>
<td>HEALTH SYSTEM: HEALTH CARE UTILISATION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical operations</td>
<td>Heart</td>
<td>Heart transplant rate</td>
<td></td>
</tr>
<tr>
<td>In-patient care utilisation</td>
<td>Aggregate bed-day rate</td>
<td></td>
<td>Median length of stay</td>
</tr>
<tr>
<td></td>
<td>Mean length of stay</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 17

**HEALTH STATUS INDICATOR FOR OTHER FORMS OF HEART DISEASE**

<table>
<thead>
<tr>
<th>OTHER FORMS OF HEART DISEASE</th>
<th>AVAILABLE</th>
<th>SHORT-TERM IMPLEMENTATION</th>
<th>LONG-TERM IMPLEMENTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HEALTH STATUS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MORTALITY</strong></td>
<td><em>ICD-9</em> 393-398, 401-405, 420-429 rate&lt;br&gt;<em>ICD-10</em> 105-109, 111-113, 130-149, 151 rate</td>
<td><em>ICD-9</em> 440, 441, 444, 415, 426-427, 428, 429 rate&lt;br&gt;<em>ICD-10</em> 170, 171, 182, 144-149, 150, 151 rate</td>
<td>Validated mortality</td>
</tr>
<tr>
<td><strong>MORBIDITY</strong></td>
<td>HDR <em>ICD-9</em> 393-398, 401-405, 420-429 rate&lt;br&gt;<em>ICD-10</em> 105-109, 111-113, 130-149, 151 rate</td>
<td>HDR 440, 441, 444, 415, 426-427, 428, 429 rate&lt;br&gt;<em>ICD-10</em> 170, 171, 182, 144-149, 150, 151 rate</td>
<td>Validated hospital discharge rate</td>
</tr>
<tr>
<td><strong>HEALTH SYSTEM:</strong>&lt;br&gt;<strong>HEALTH CARE UTILISATION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In patient care utilisation&lt;br&gt;surgical operations and&lt;br&gt;invasive procedures</td>
<td>Mean length of stay&lt;br&gt;Aggregate bed-day rate</td>
<td>HDR rates for&lt;br&gt;surgical operations,&lt;br&gt;invasive procedures:&lt;br&gt;Valvular operations,&lt;br&gt;Aortic and other&lt;br&gt;aneurism,&lt;br&gt;Pace maker,&lt;br&gt;Catheter ablation,&lt;br&gt;Implantable&lt;br&gt;cardioverter&lt;br&gt;defibrillators</td>
<td>Mean length of stay</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 18

**HEALTH STATUS INDICATORS FOR CEREBROVASCULAR DISEASES**

(ICD-9 430-438, ICD-10 I60-I69, G45)

<table>
<thead>
<tr>
<th>HEALTH STATUS</th>
<th>AVAILABLE</th>
<th>SHORT-TERM IMPLEMENTATION</th>
<th>LONG-TERM IMPLEMENTATION</th>
</tr>
</thead>
</table>
| **MORTALITY** | **ICD-9** 430-438, 290.4 rate  
**ICD-10** I60-I69, G45, F01 rate | **ICD-9** 430, 431+432, 434, 436+437 rate  
**ICD-10** I60, I61+I62, I66, I64+I67, I68 rate | |
| **MORBIDITY** | HDR **ICD-9** 430–438, 290.4  
**ICD-10** I60-I69, G45, F01 | HDR **ICD-9** 430, 431+432, 434, 436+437  
**ICD-10** I60, I61+I62, I66, I64+I67  
Attack rate/ incidence 7-day case-fatality rate | Attack rate / incidence by subtype of stroke  
(ischaemic subarachnoid, intracerebral haemorrhagic)  
Prevalence |
| **DISABILITY** | | | Functional disability and quality of life indicators |
| **HEALTH SYSTEM: HEALTH CARE UTILISATION** | | | |
| In-patient care utilisation | Aggregate bed-day rate  
Mean length of stay  
Carotid angioplasty rate | CT, MRI per population  
Median length of stay | Stroke units per population |
REFERENCES


11. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and


49. http://www3.who.int/whosis/menu.cfm/

50. http://www.euro.who.int/HFADB.


52. http://europa.eu.int/comm/eurostat/Public/datashop/print-
catalogue/EN?catalogue=Eurostat&collection=13-Pocketbooks&product=KS-43-02-866-
C-EN.


54. A disease-based comparison of health systems: what is best and at what cost? Proceedings of


59. Clinical Evidence; the international source of the best available evidence for effective health


IX Revision, WHO 1977.

63. Manual of the International Statistical Classification of Diseases and Related Health Problems,

64. NOMESCO Classification of Surgical Procedures Version 1.7. NOMESCO Uppsala and
Copenhagen 2002 (www.nordclass.uu.se/verksam/ncspe.htm)

65. Beaglehole R, Stewart A, Butler M. Comparability of old and New World Health Organization


68. Tunstall-Pedoe H: Comment on the ESC/ACC redefinition of Myocardial infarction by consensus dissenter. Eur Heart J 2001; **22**, 7, 613-615


70. The Task Force on Heart Failure of the ESC. *Eur Heart J* 1995; **16**:741-51.


This report was produced by a contractor for Health & Consumer Protection Directorate General and represents the views of the contractor or author. These views have not been adopted or in any way approved by the Commission and do not necessarily represent the view of the Commission or the Directorate General for Health and Consumer Protection. The European Commission does not guarantee the accuracy of the data included in this study, nor does it accept responsibility for any use made thereof.